

```
!!AA_SEQUENCE 1.0
ID   Q6KA74_ORYSA  PRELIMINARY;  PRT;   633 AA.
AC   Q6KA74;
DT   05-JUL-2004, integrated into UniProtKB/TrEMBL.
DT   05-JUL-2004, sequence version 1.
DT   07-FEB-2006, entry version 9.
DE   Ankyrin repeat protein-like.
GN   Name=QJ1112.G06.34;
OS   Oryza sativa (japonica cultivar-group).
OC   Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC   Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; BEP clade;
OC   Ehrhartoideae; Oryzaceae; Oryza.
OX   NCBI_TaxID=39947;
RN   [1]
RP   NUCLEOTIDE SEQUENCE.
RA   Sasaki T., Matsumoto T., Yamamoto K.;
RL   Submitted (AUG-2001) to the EMBL/GenBank/DBJ databases.
CC   -----
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----
CC   EMBL: AP003996; BAD19146.1; -; Genomic_DNA.
CC   Gramene; Q6KA74; -;
CC   InterPro; IPR002110; ANK.
CC   Pfam; PF00023; Ank; 1.
CC   PROSITE; PS50297; ANK_REPEAT_REGION; 1.
CC   PROSITE; PS50088; ANK_REPEAT; 1.
CC   ANK repeat; Repeat.
KW   ANK repeat; Repeat.
SQ   SEQUENCE 633 AA; 70287 MW; 09B9399F91F22BD1 CRC64;

Q6KA74_ORYSA Length: 633 February 14, 2007 16:02 Type: P Check: 7693 ..

1  MEDASKYVHS PAHLAVVRD HASLRLVAG LPRLPRADEV ATEESIIAGE
51  AVADAVSAAI DRDVPRET PLHLAVLRD PVAADILMSA GADWSLQAD
101 GWSALQEAVC TREDATATII ARHYQPLAWA KWCRRLPVL ASINRIRDFY
151 MEISFHFESS VIPFIGRIAP SDTYRIWKRG AALRADMTLA GPDGPFRIQS
201 DQTFLEFLGDG ARPEDAGGKE LHPGSLIVLA HKDKEITDAL EGAGVQPTFA
251 EVAHEVALMS KTNMYRPGID VTQAEIVPHL NWRRQERTEA VGHWKAKVYD
301 MLNVLTVKS RRVPGNMTDE ELFAMEGEEK NGRCTELDAE LDEVLTAEER
351 KQLDSALRMG NOEEFEERC BEGGADHL DANGVAKKK GWFGWGGKKG
401 TKNDKPSKA NQGSKDESD LGKGKEKNS KKKKGASSGD STKHESEYKK
451 GLRPVLWLTG DFPLKTDELI PLLDVLANV KAVRRLRELL TTKLPPGTFF
501 VKTAIPVPT IRVIVTFKFE BELQPLDEFA TPPSSPTQFQ DAGKSEGS
551 GSWYSWVRGG RGAQSSDSGD SRNWKDEVDV FQIPSDYTWV DANCKRRMK
601 AKKAKNRGS TRKQSKSKTS SEGCHPMMDG FEE
```

```

!!AA_SEQUENCE 1.0
ID _ADO34231 standard; peptide; 18 AA.
XX AC ADO34231;
XX DT 12-AUG-2004 (first entry)
XX DE Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 8.
XX XX
XX KW apolipoprotein-E mimicking polypeptide; antilipaemic; cardiatic;
XX KW vasotropic; antiarteriosclerotic; cerebroprotective; antianginal;
XX KW serum cholesterol; coronary artery disease; dysbetalipoproteinaemia;
XX KW atherosclerosis; myocardial infarction; stroke; embolus; angina;
XX KW low-density lipoprotein; LDL; very low density lipoprotein; VLDL.
XX OS Synthetic.
XX XX
XX PN WO2004043403-A2.
XX PD 27-MAY-2004.
XX PF 13-NOV-2003; 2003WO-US036268.
XX PR 13-NOV-2002; 2002US-0425821P.
XX PA (UABR-) UAB RES FOUND.
XX PI Anantharamiah GM, Garber DW, Datta G;
XX DR WPI; 2004-411629/38.
XX XX
XX PT Synthetic apolipoprotein-E mimicking polypeptide useful for treating
XX PT coronary artery disease, dysbetalipoproteinemia or atherosclerosis
XX PT comprises an amino acid sequence.
XX PS Claim 4; SEQ ID NO 8; 79pp; English.
XX CC The invention relates to a novel synthetic apolipoprotein-E mimicking
XX CC polypeptide. The invention further comprises an isolated nucleic acid
XX CC encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector,
XX CC a host cell, a recombinant cell or a transgenic, non-human subject
XX CC (including animal or plant) comprising the synthetic apolipoprotein-E
XX CC mimicking polypeptide encoding polynucleotide; a composition comprising
XX CC the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and
XX CC an monoclonal antibody that specifically binds to the synthetic
XX CC apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E
XX CC mimicking polypeptide has the following activities: antilipaemic,
XX CC cardiatic, vasotropic, antiarteriosclerotic, cerebroprotective, and
XX CC antianginal. The synthetic apolipoprotein-E mimicking polypeptide is
XX CC useful for reducing serum cholesterol in a subject (including a mammal
XX CC such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape,
XX CC chimpanzee or orangutan); for treating coronary artery disease,
XX CC dysbetalipoproteinaemia or atherosclerosis; and for reducing the risk of
XX CC myocardial infarction or stroke; for breaking an embolus in the subject;
XX CC and also for treating angina. The synthetic apolipoprotein-E mimicking
XX CC polypeptide enhances binding of low-density lipoprotein (LDL) or very low
XX CC density lipoprotein (VLDL) to a cell and enhances degradation of LDL or
XX CC VLDL by a cell. This sequence represents a synthetic apolipoprotein-E
XX CC mimicking polypeptide of the invention.
XX SQ Sequence 18 AA;
AD034231 Length: 18 February 14, 2007 16:01 Type: P Check: 3010 ..
1 GIRFLGSIW RFIRAFYG
!!AA_SEQUENCE 1.0
ID _ADO34334 standard; peptide; 18 AA.
XX AC ADO34334;
XX DT 12-AUG-2004 (first entry)
XX DE Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 131.
XX XX
XX KW apolipoprotein-E mimicking polypeptide; antilipaemic; cardiatic;
XX KW vasotropic; antiarteriosclerotic; cerebroprotective; antianginal;
XX KW serum cholesterol; coronary artery disease; dysbetalipoproteinaemia;
XX KW atherosclerosis; myocardial infarction; stroke; embolus; angina;
XX KW low-density lipoprotein; LDL; very low density lipoprotein; VLDL.
XX OS Synthetic.
XX XX
XX PN WO2004043403-A2.
XX PD 27-MAY-2004.
XX PF 13-NOV-2003; 2003WO-US036268.
XX PR 13-NOV-2002; 2002US-0425821P.
XX PA (UABR-) UAB RES FOUND.
XX PI Anantharamiah GM, Garber DW, Datta G;
XX DR WPI; 2004-411629/38.
XX XX
XX PT Synthetic apolipoprotein-E mimicking polypeptide useful for treating
XX PT coronary artery disease, dysbetalipoproteinemia or atherosclerosis
XX PT comprises an amino acid sequence.
XX PS Claim 4; SEQ ID NO 8; 79pp; English.
XX CC The invention relates to a novel synthetic apolipoprotein-E mimicking
XX CC polypeptide. The invention further comprises an isolated nucleic acid
XX CC encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector,
XX CC a host cell, a recombinant cell or a transgenic, non-human subject
XX CC (including animal or plant) comprising the synthetic apolipoprotein-E
XX CC mimicking polypeptide encoding polynucleotide; a composition comprising
XX CC the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and
XX CC an monoclonal antibody that specifically binds to the synthetic
XX CC apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E
XX CC mimicking polypeptide has the following activities: antilipaemic,
XX CC cardiatic, vasotropic, antiarteriosclerotic, cerebroprotective, and
XX CC antianginal. The synthetic apolipoprotein-E mimicking polypeptide is
XX CC useful for reducing serum cholesterol in a subject (including a mammal
XX CC such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape,
XX CC chimpanzee or orangutan); for treating coronary artery disease,
XX CC dysbetalipoproteinaemia or atherosclerosis; and for reducing the risk of
XX CC myocardial infarction or stroke; for breaking an embolus in the subject;
XX CC and also for treating angina. The synthetic apolipoprotein-E mimicking
XX CC polypeptide enhances binding of low-density lipoprotein (LDL) or very low
XX CC density lipoprotein (VLDL) to a cell and enhances degradation of LDL or
XX CC VLDL by a cell. This sequence represents a synthetic apolipoprotein-E
XX CC mimicking polypeptide of the invention.
XX SQ Sequence 18 AA;
AD034334 Length: 18 February 14, 2007 16:01 Type: P Check: 3037 ..
1 GFRRLGSIW RIFRAIYG
!!AA_SEQUENCE 1.0
ID _ADO34354 standard; peptide; 18 AA.
XX AC ADO34354;
XX DT 12-AUG-2004 (first entry)
XX DE Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 131.
XX XX
XX KW apolipoprotein-E mimicking polypeptide; antilipaemic; cardiatic;
XX KW vasotropic; antiarteriosclerotic; cerebroprotective; antianginal;
XX KW serum cholesterol; coronary artery disease; dysbetalipoproteinaemia;
XX KW atherosclerosis; myocardial infarction; stroke; embolus; angina;
XX KW low-density lipoprotein; LDL; very low density lipoprotein; VLDL.

```

```

XX OS Synthetic.
XX PN WO2004043403-A2.
XX PD 27-MAY-2004.
XX PF 13-NOV-2003; 2003WO-US036268.
XX PR 13-NOV-2002; 2002US-0425821P.
XX PA (UABR-) UAB RES FOUND.
XX PI Anantharamiah GM, Garber DW, Datta G;
XX DR WPI; 2004-411629/38.
XX CC Synthetic apolipoprotein-E mimicking polypeptide useful for treating
PT coronary artery disease, dysbetalipoproteinemia or atherosclerosis
PT comprises an amino acid sequence.
XX PS Claim 4; SEQ ID NO 131; 79pp; English.
XX CC The invention relates to a novel synthetic apolipoprotein-E mimicking
CC polypeptide. The invention further comprises an isolated nucleic acid
CC encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector,
CC a host cell, a recombinant cell or a transgenic, non-human subject
CC (including animal or plant) comprising the synthetic apolipoprotein-E
CC mimicking polypeptide encoding polynucleotide; a composition comprising
CC the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and
CC an monoclonal antibody that specifically binds to the synthetic
CC apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E
CC mimicking polypeptide has the following activities: antilipemic,
CC cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and
CC antidiabetic. The synthetic apolipoprotein-E mimicking polypeptide is
CC useful for reducing serum cholesterol in a subject (including a mammal
CC such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape,
CC chimpanzee or orangutan); for treating coronary artery disease,
CC dysbetalipoproteinemia or atherosclerosis; and for reducing the risk of
CC myocardial infarction or stroke; for breaking an embolus in the subject;
CC and also for treating angina. The synthetic apolipoprotein-E mimicking
CC polypeptide enhances binding of low-density lipoprotein (LDL) or very low
CC density lipoprotein (VLDL) to a cell and enhances degradation of LDL or
CC VLDL by a cell. This sequence represents a synthetic apolipoprotein-E
CC mimicking polypeptide of the invention.
XX SQ Sequence 18 AA;
AD034354 Length: 18 February 14, 2007 16:01 Type: P Check: 3055
1 GLRFLGSIW RFLAFYG
!!AA_SEQUENCE 1.0
ID AD034373 standard; peptide; 14 AA.
XX AC AD034373;
XX DT 12-AUG-2004 (first entry)
XX DE Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 150.
XX KW apolipoprotein-E mimicking polypeptide; antilipemic; cardiant;
KW vasotropic; antiarteriosclerotic; cerebroprotective; antidiabetic;
KW serum cholesterol; coronary artery disease; dysbetalipoproteinemia;
KW atherosclerosis; myocardial infarction; stroke; embolus; angina;
KW low-density lipoprotein; LDL; very low density lipoprotein; VLDL.
XX OS Synthetic.
XX PN WO2004043403-A2.
XX PD 27-MAY-2004.

```

```

PF 13-NOV-2003; 2003WO-US036268.
XX PR 13-NOV-2002; 2002US-0425821P.
XX PA (UABR-) UAB RES FOUND.
XX PI Anantharamiah GM, Garber DW, Datta G;
XX DR WPI; 2004-411629/38.
XX CC Synthetic apolipoprotein-E mimicking polypeptide useful for treating
PT coronary artery disease, dysbetalipoproteinemia or atherosclerosis
PT comprises an amino acid sequence.
XX PS Claim 4; SEQ ID NO 150; 79pp; English.
XX CC The invention relates to a novel synthetic apolipoprotein-E mimicking
CC polypeptide. The invention further comprises an isolated nucleic acid
CC encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector,
CC a host cell, a recombinant cell or a transgenic, non-human subject
CC (including animal or plant) comprising the synthetic apolipoprotein-E
CC mimicking polypeptide encoding polynucleotide; a composition comprising
CC the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and
CC an monoclonal antibody that specifically binds to the synthetic
CC apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E
CC mimicking polypeptide has the following activities: antilipemic,
CC cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and
CC antidiabetic. The synthetic apolipoprotein-E mimicking polypeptide is
CC useful for reducing serum cholesterol in a subject (including a mammal
CC such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape,
CC chimpanzee or orangutan); for treating coronary artery disease,
CC dysbetalipoproteinemia or atherosclerosis; and for reducing the risk of
CC myocardial infarction or stroke; for breaking an embolus in the subject;
CC and also for treating angina. The synthetic apolipoprotein-E mimicking
CC polypeptide enhances binding of low-density lipoprotein (LDL) or very low
CC density lipoprotein (VLDL) to a cell and enhances degradation of LDL or
CC VLDL by a cell. This sequence represents a synthetic apolipoprotein-E
CC mimicking polypeptide of the invention.
XX SQ Sequence 14 AA;
AD034373 Length: 14 February 14, 2007 16:01 Type: P Check: 8199
1 GIRREYGSIW RIFR
!!AA_SEQUENCE 1.0
ID AD034382 standard; peptide; 14 AA.
XX AC AD034382;
XX DT 12-AUG-2004 (first entry)
XX DE Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 159.
XX KW apolipoprotein-E mimicking polypeptide; antilipemic; cardiant;
KW vasotropic; antiarteriosclerotic; cerebroprotective; antidiabetic;
KW serum cholesterol; coronary artery disease; dysbetalipoproteinemia;
KW atherosclerosis; myocardial infarction; stroke; embolus; angina;
KW low-density lipoprotein; LDL; very low density lipoprotein; VLDL.
XX OS Synthetic.
XX PN WO2004043403-A2..
XX PD 27-MAY-2004.
XX PF 13-NOV-2003; 2003WO-US036268.
XX PR 13-NOV-2002; 2002US-0425821P.
XX PA (UABR-) UAB RES FOUND.
XX PI Anantharamiah GM, Garber DW, Datta G;

```

XX DR WPI; 2004-411629/38.
 XX CC Synthetic apolipoprotein-E mimicking polypeptide useful for treating
 PT coronary artery disease, dysbetalipoproteinemia or atherosclerosis
 PT comprises an amino acid sequence.
 XX CC
 XX PS Claim 4; SEQ ID NO 159; 79pp; English.
 XX CC The invention relates to a novel synthetic apolipoprotein-E mimicking
 CC polypeptide. The invention further comprises an isolated nucleic acid
 CC encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector,
 CC a host cell, a recombinant cell or a transgenic, non-human subject
 CC (including animal or plant) comprising the synthetic apolipoprotein-E
 CC mimicking polypeptide encoding polynucleotide; a composition comprising
 CC the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and
 CC an monoclonal antibody that specifically binds to the synthetic
 CC apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E
 CC mimicking polypeptide has the following activities: antilipemic,
 CC cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and
 CC antianginal. The synthetic apolipoprotein-E mimicking polypeptide is
 CC useful for reducing serum cholesterol in a subject (including a mammal
 CC such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape,
 CC chimpanzee or orangutan); for treating coronary artery disease,
 CC dysbetalipoproteinemia or atherosclerosis; and for reducing the risk of
 CC myocardial infarction or stroke; for breaking an embolus in the subject;
 CC and also for treating angina. The synthetic apolipoprotein-E mimicking
 CC polypeptide enhances binding of low-density lipoprotein (LDL) or very low
 CC density lipoprotein (VLDL) to a cell and enhances degradation of LDL or
 CC VLDL by a cell. This sequence represents a synthetic apolipoprotein-E
 CC mimicking polypeptide of the invention.
 XX CC
 XX SQ Sequence 14 AA;
 AD034382 Length: 14 February 14, 2007 16:01 Type: P Check: 8222 ..
 1 GIRRYFGSIW RFLR
 !!AA SEQUENCE 1.0
 ID AD034382 standard; peptide; 14 AA.
 XX AC AD034382;
 XX DT 12-AUG-2004 (first entry)
 XX DE Synthetic apolipoprotein-E mimicking peptide, SEQ ID NO 145.
 KW apolipoprotein-E mimicking polypeptide; antilipemic; cardiant;
 KW vasotropic; antiarteriosclerotic; cerebroprotective; antianginal;
 KW serum cholesterol; coronary artery disease; dysbetalipoproteinemia;
 KW atherosclerosis; myocardial infarction; stroke; embolus; angina;
 KW low-density lipoprotein; LDL; very low density lipoprotein; VLDL.
 XX OS Synthetic.
 XX WO2004043403-A2.
 XX PN 27-MAY-2004.
 XX PD 13-NOV-2003; 2003WO-US036268.
 XX PF 13-NOV-2002; 2002US-0425821P.
 XX PR (UABR-) UAB RES FOUND.
 XX PA Anantharamiah GM, Garber DW, Datta G;
 XX PI WPI; 2004-411629/38.
 XX DR Synthetic apolipoprotein-E mimicking polypeptide useful for treating
 PT coronary artery disease, dysbetalipoproteinemia or atherosclerosis
 PT comprises an amino acid sequence.
 XX CC

PS Claim 4; SEQ ID NO 145; 79pp; English.
 XX CC The invention relates to a novel synthetic apolipoprotein-E mimicking
 CC polypeptide. The invention further comprises an isolated nucleic acid
 CC encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector,
 CC a host cell, a recombinant cell or a transgenic, non-human subject
 CC (including animal or plant) comprising the synthetic apolipoprotein-E
 CC mimicking polypeptide encoding polynucleotide; a composition comprising
 CC the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and
 CC an monoclonal antibody that specifically binds to the synthetic
 CC apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E
 CC mimicking polypeptide has the following activities: antilipemic,
 CC cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and
 CC antianginal. The synthetic apolipoprotein-E mimicking polypeptide is
 CC useful for reducing serum cholesterol in a subject (including a mammal
 CC such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape,
 CC chimpanzee or orangutan); for treating coronary artery disease,
 CC dysbetalipoproteinemia or atherosclerosis; and for reducing the risk of
 CC myocardial infarction or stroke; for breaking an embolus in the subject;
 CC and also for treating angina. The synthetic apolipoprotein-E mimicking
 CC polypeptide enhances binding of low-density lipoprotein (LDL) or very low
 CC density lipoprotein (VLDL) to a cell and enhances degradation of LDL or
 CC VLDL by a cell. This sequence represents a synthetic apolipoprotein-E
 CC mimicking polypeptide of the invention.
 XX CC
 XX SQ Sequence 14 AA;
 AD034368 Length: 14 February 14, 2007 16:01 Type: P Check: 8268 ..
 1 GIRRYFGSLW RFLR
 !!AA SEQUENCE 1.0
 ID AD034381 standard; peptide; 14 AA.
 XX AC AD034381;
 XX DT 12-AUG-2004 (first entry)
 XX DE Synthetic apolipoprotein-E mimicking peptide, SEQ ID NO 158.
 KW apolipoprotein-E mimicking polypeptide; antilipemic; cardiant;
 KW vasotropic; antiarteriosclerotic; cerebroprotective; antianginal;
 KW serum cholesterol; coronary artery disease; dysbetalipoproteinemia;
 KW atherosclerosis; myocardial infarction; stroke; embolus; angina;
 KW low-density lipoprotein; LDL; very low density lipoprotein; VLDL.
 XX OS Synthetic.
 XX WO2004043403-A2.
 XX PN 27-MAY-2004.
 XX PD 13-NOV-2003; 2003WO-US036268.
 XX PF 13-NOV-2002; 2002US-0425821P.
 XX PR (UABR-) UAB RES FOUND.
 XX PA Anantharamiah GM, Garber DW, Datta G;
 XX PI WPI; 2004-411629/38.
 XX DR Synthetic apolipoprotein-E mimicking polypeptide useful for treating
 PT coronary artery disease, dysbetalipoproteinemia or atherosclerosis
 PT comprises an amino acid sequence.
 XX CC
 XX PS Claim 4; SEQ ID NO 158; 79pp; English.
 XX CC The invention relates to a novel synthetic apolipoprotein-E mimicking
 CC polypeptide. The invention further comprises an isolated nucleic acid
 CC encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector,
 CC a host cell, a recombinant cell or a transgenic, non-human subject
 CC (including animal or plant) comprising the synthetic apolipoprotein-E
 CC mimicking polypeptide encoding polynucleotide; a composition comprising
 CC the synthetic apolipoprotein-E mimicking polypeptide and a carrier;
 CC and also for treating angina. The synthetic apolipoprotein-E mimicking
 CC polypeptide enhances binding of low-density lipoprotein (LDL) or very low
 CC density lipoprotein (VLDL) to a cell and enhances degradation of LDL or
 CC VLDL by a cell. This sequence represents a synthetic apolipoprotein-E
 CC mimicking polypeptide of the invention.
 XX CC

CC mimicking polypeptide encoding polynucleotide; a composition comprising
 CC the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and
 CC an monoclonal antibody that specifically binds to the synthetic
 CC apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E
 CC mimicking polypeptide has the following activities: antilipaeamic,
 CC cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and
 CC antianginal. The synthetic apolipoprotein-E mimicking polypeptide is
 CC useful for reducing serum cholesterol in a subject (including a mammal
 CC such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape,
 CC chimpanzee or orangutan); for treating coronary artery disease,
 CC dysbetalipoproteinemia or atherosclerosis; and for reducing the risk of
 CC myocardial infarction or stroke; for breaking an embolus in the subject;
 CC and also for treating angina. The synthetic apolipoprotein-E mimicking
 CC polypeptide enhances binding of low-density lipoprotein (LDL) or very low
 CC density lipoprotein (VLDL) to a cell and enhances degradation of LDL or
 CC VLDL by a cell. This sequence represents a synthetic apolipoprotein-E
 CC mimicking polypeptide of the invention.

XX
 SQ Sequence 14 AA;

ADO34391 Length: 14 February 14, 2007 16:01 Type: P Check: 8183

1 GIRRFYGSIW RIFR

!!AA_SEQUENCE 1.0
 ID ADO34391 standard; peptide; 14 AA.

AC ADO34391;

DT 12-AUG-2004 (first entry)

XX Synthetic apolipoprotein-E mimicking peptide, SEQ ID NO 168.

XX apolipoprotein-E mimicking polypeptide; antilipaeamic; cardiant;
 KW vasotropic; antiarteriosclerotic; cerebroprotective; antianginal;
 KW serum cholesterol; coronary artery disease; dysbetalipoproteinemia;
 KW atherosclerosis; myocardial infarction; stroke; embolus; angina;
 KW low-density lipoprotein; LDL; very low density lipoprotein; VLDL.

OS Synthetic.

XX WO2004043403-A2.

XX 27-MAY-2004.

XX 13-NOV-2003; 2003WO-US036268.

XX 13-NOV-2002; 2002US-0425821P.

XX (UABR-) UAB RES FOUND.

XX Anantharamiah GM, Garber DW, Datta G;

XX WPI; 2004-411629/38.

XX Synthetic apolipoprotein-E mimicking polypeptide useful for treating
 PT coronary artery disease, dysbetalipoproteinemia or atherosclerosis
 PT comprises an amino acid sequence.

XX Claim 4; SEQ ID NO 168; 79pp; English.

XX The invention relates to a novel synthetic apolipoprotein-E mimicking
 CC polypeptide. The invention further comprises an isolated nucleic acid
 CC encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector,
 CC a host cell, a recombinant cell or a transgenic, non-human subject
 CC (including animal or plant) comprising the synthetic apolipoprotein-E
 CC mimicking polypeptide encoding polynucleotide; a composition comprising
 CC the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and
 CC an monoclonal antibody that specifically binds to the synthetic
 CC apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E
 CC mimicking polypeptide has the following activities: antilipaeamic,
 CC cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and
 CC antianginal. The synthetic apolipoprotein-E mimicking polypeptide is

CC useful for reducing serum cholesterol in a subject (including a mammal
 CC such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape,
 CC chimpanzee or orangutan); for treating coronary artery disease,
 CC dysbetalipoproteinemia or atherosclerosis; and for reducing the risk of
 CC myocardial infarction or stroke; for breaking an embolus in the subject;
 CC and also for treating angina. The synthetic apolipoprotein-E mimicking
 CC polypeptide enhances binding of low-density lipoprotein (LDL) or very low
 CC density lipoprotein (VLDL) to a cell and enhances degradation of LDL or
 CC VLDL by a cell. This sequence represents a synthetic apolipoprotein-E
 CC mimicking polypeptide of the invention.

XX Sequence 14 AA;

ADO34391 Length: 14 February 14, 2007 16:01 Type: P Check: 8199

1 GIRRFYGSIW RIFR

!!AA_SEQUENCE 1.0

ID ADO34427 standard; peptide; 14 AA.

AC ADO34427;

DT 12-AUG-2004 (first entry)

XX Synthetic apolipoprotein-E mimicking peptide, SEQ ID NO 204.

XX apolipoprotein-E mimicking polypeptide; antilipaeamic; cardiant;
 KW vasotropic; antiarteriosclerotic; cerebroprotective; antianginal;
 KW serum cholesterol; coronary artery disease; dysbetalipoproteinemia;
 KW atherosclerosis; myocardial infarction; stroke; embolus; angina;
 KW low-density lipoprotein; LDL; very low density lipoprotein; VLDL.

OS Synthetic.

XX WO2004043403-A2.

XX 27-MAY-2004.

XX 13-NOV-2003; 2003WO-US036268.

XX 13-NOV-2002; 2002US-0425821P.

XX (UABR-) UAB RES FOUND.

XX Anantharamiah GM, Garber DW, Datta G;

XX WPI; 2004-411629/38.

XX Synthetic apolipoprotein-E mimicking polypeptide useful for treating
 PT coronary artery disease, dysbetalipoproteinemia or atherosclerosis
 PT comprises an amino acid sequence.

XX Claim 4; SEQ ID NO 204; 79pp; English.

XX The invention relates to a novel synthetic apolipoprotein-E mimicking
 CC polypeptide. The invention further comprises an isolated nucleic acid
 CC encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector,
 CC a host cell, a recombinant cell or a transgenic, non-human subject
 CC (including animal or plant) comprising the synthetic apolipoprotein-E
 CC mimicking polypeptide encoding polynucleotide; a composition comprising
 CC the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and
 CC an monoclonal antibody that specifically binds to the synthetic
 CC apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E
 CC mimicking polypeptide has the following activities: antilipaeamic,
 CC cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and
 CC antianginal. The synthetic apolipoprotein-E mimicking polypeptide is
 CC useful for reducing serum cholesterol in a subject (including a mammal
 CC such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape,
 CC chimpanzee or orangutan); for treating coronary artery disease,
 CC dysbetalipoproteinemia or atherosclerosis; and for reducing the risk of
 CC myocardial infarction or stroke; for breaking an embolus in the subject;
 CC and also for treating angina. The synthetic apolipoprotein-E mimicking
 CC polypeptide enhances binding of low-density lipoprotein (LDL) or very low

CC density lipoprotein (VLDL) to a cell and enhances degradation of LDL or
CC VLDL by a cell. This sequence represents a synthetic apolipoprotein-E
CC mimicking polypeptide of the invention.
XX
SQ Sequence 14 AA;
ADO34427 Length: 14 February 14, 2007 16:01 Type: P Check: 8180 ..
1 GIRRYFGSIW RIFR
!!AA SEQUENCE 1.0
ID ADO34225 standard; peptide; 18 AA.
XX AC ADO34225;
XX DT 12-AUG-2004 (first entry)
XX DE Synthetic apolipoprotein-E mimicking polypeptide related R18L peptide.
XX KW apolipoprotein-E mimicking polypeptide; antilipaeamic; cardiant;
KW vasotropic; antiarteriosclerotic; cerebroprotective; antianginal;
KW serum cholesterol; coronary artery disease; dysbetalipoproteinaemia;
KW atherosclerosis; myocardial infarction; stroke; embolus; angina;
KW low-density lipoprotein; LDL; very low density lipoprotein; VLDL.
XX OS Synthetic.
XX FH Key Location/Qualifiers
FT Modified-site 1
FT Modified-site 1 /note= "N-terminal acetyl"
FT Modified-site 18
FT Modified-site 18 /note= "C-terminal amide"
XX PN WO2004043403-A2.
XX PD 27-MAY-2004.
XX PF 13-NOV-2003; 2003WO-US036268.
XX PR 13-NOV-2002; 2002US-0425821P.
XX PA (UABR-) UAB RES FOUND.
XX PI Anantharamiah GM, Garber DW, Datta G;
XX DR WPI; 2004-411629/38.
XX Synthetic apolipoprotein-E mimicking polypeptide useful for treating
PT coronary artery disease, dysbetalipoproteinemia or atherosclerosis
PT comprises an amino acid sequence.
XX
PS Claim 4; SEQ ID NO 2; 79pp; English.
XX The invention relates to a novel synthetic apolipoprotein-E mimicking
CC polypeptide. The invention further comprises an isolated nucleic acid
CC encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector,
CC a host cell, a recombinant cell or a transgenic, non-human subject
CC (including animal or plant) comprising the synthetic apolipoprotein-E
CC mimicking polypeptide encoding polynucleotide; a composition comprising
CC the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and
CC an monoclonal antibody that specifically binds to the synthetic
CC apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E
CC mimicking polypeptide has the following activities: antilipaeamic,
CC cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and
CC antianginal. The synthetic apolipoprotein-E mimicking polypeptide is
CC useful for reducing serum cholesterol in a subject (including a mammal
CC chimpanzee or orangutan); for treating coronary artery disease,
CC dysbetalipoproteinaemia or atherosclerosis; and for reducing the risk of
CC myocardial infarction or stroke; for breaking an embolus in the subject;
CC and also for treating angina. The synthetic apolipoprotein-E mimicking
CC polypeptide enhances binding of low-density lipoprotein (LDL) or very low
CC density lipoprotein (VLDL) to a cell and enhances degradation of LDL or

CC VLDL by a cell. This sequence represents a synthetic apolipoprotein-E
CC mimicking polypeptide of the invention.
XX
SQ Sequence 18 AA;
ADO34225 Length: 18 February 14, 2007 16:01 Type: P Check: 3010 ..
1 GIRRFLGSIW REIRAFYG
!!AA SEQUENCE 1.0
ID ADO34336 standard; peptide; 18 AA.
XX AC ADO34336;
XX DT 12-AUG-2004 (first entry)
XX DE Synthetic apolipoprotein-E mimicking peptide, SEQ ID NO 113.
XX KW apolipoprotein-E mimicking polypeptide; antilipaeamic; cardiant;
KW vasotropic; antiarteriosclerotic; cerebroprotective; antianginal;
KW serum cholesterol; coronary artery disease; dysbetalipoproteinaemia;
KW atherosclerosis; myocardial infarction; stroke; embolus; angina;
KW low-density lipoprotein; LDL; very low density lipoprotein; VLDL.
XX OS Synthetic.
XX PN WO2004043403-A2.
XX PD 27-MAY-2004.
XX PF 13-NOV-2003; 2003WO-US036268.
XX PR 13-NOV-2002; 2002US-0425821P.
XX PA (UABR-) UAB RES FOUND.
XX PI Anantharamiah GM, Garber DW, Datta G;
XX DR WPI; 2004-411629/38.
XX Synthetic apolipoprotein-E mimicking polypeptide useful for treating
PT coronary artery disease, dysbetalipoproteinemia or atherosclerosis
PT comprises an amino acid sequence.
XX
PS Claim 4; SEQ ID NO 113; 79pp; English.
XX The invention relates to a novel synthetic apolipoprotein-E mimicking
CC polypeptide. The invention further comprises an isolated nucleic acid
CC encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector,
CC a host cell, a recombinant cell or a transgenic, non-human subject
CC (including animal or plant) comprising the synthetic apolipoprotein-E
CC mimicking polypeptide encoding polynucleotide; a composition comprising
CC the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and
CC an monoclonal antibody that specifically binds to the synthetic
CC apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E
CC mimicking polypeptide has the following activities: antilipaeamic,
CC cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and
CC antianginal. The synthetic apolipoprotein-E mimicking polypeptide is
CC useful for reducing serum cholesterol in a subject (including a mammal
CC chimpanzee or orangutan); for treating coronary artery disease,
CC dysbetalipoproteinaemia or atherosclerosis; and for reducing the risk of
CC myocardial infarction or stroke; for breaking an embolus in the subject;
CC and also for treating angina. The synthetic apolipoprotein-E mimicking
CC polypeptide enhances binding of low-density lipoprotein (LDL) or very low
CC density lipoprotein (VLDL) to a cell and enhances degradation of LDL or
CC VLDL by a cell. This sequence represents a synthetic apolipoprotein-E
CC mimicking polypeptide of the invention.
XX
SQ Sequence 18 AA;
ADO34336 Length: 18 February 14, 2007 16:01 Type: P Check: 3007 ..

```

1 GRRFLGSIW RIFRAFYG
!!AA SEQUENCE 1.0
ID_ADO34338 standard; peptide; 18 AA.
XX AC ADO34338;
XX DT 12-AUG-2004 (first entry)
XX DE Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 115.
XX KW apolipoprotein-E mimicking polypeptide; antilipaeamic; cardiant;
XX KW vasotropic; antiarteriosclerotic; cerebroprotective; antianginal;
XX KW serum cholesterol; coronary artery disease; dysbetalipoproteinaemia;
XX KW atherosclerosis; myocardial infarction; stroke; embolus; angina;
XX KW low-density lipoprotein; LDL; very low density lipoprotein; VLDL.
XX OS Synthetic.
XX PN WO2004043403-A2.
XX PD 27-MAY-2004.
XX PF 13-NOV-2003; 2003WO-US036268.
XX PR 13-NOV-2002; 2002US-0425821P.
XX PA (UABR-) UAB RES FOUND.
XX PI Anantharamiah GM, Garber DW, Datta G;
XX DR WPI; 2004-411629/38.
XX PT Synthetic apolipoprotein-E mimicking polypeptide useful for treating
XX PT coronary artery disease, dysbetalipoproteinemia or atherosclerosis
XX PT comprises an amino acid sequence.
XX PS Claim 4; SEQ ID NO 115; 79pp; English.
XX CC The invention relates to a novel synthetic apolipoprotein-E mimicking
XX CC polypeptide. The invention further comprises an isolated nucleic acid
XX CC encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector,
XX CC a host cell, a recombinant cell or a transgenic, non-human subject
XX CC (including animal or plant) comprising the synthetic apolipoprotein-E
XX CC mimicking polypeptide encoding polynucleotide; a composition comprising
XX CC the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and
XX CC an monoclonal antibody that specifically binds to the synthetic
XX CC apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E
XX CC mimicking polypeptide has the following activities: antilipaeamic,
XX CC cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and
XX CC antianginal. The synthetic apolipoprotein-E mimicking polypeptide is
XX CC useful for reducing serum cholesterol in a subject (including a mammal
XX CC such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape,
XX CC chimpanzee or orangutan); for treating coronary artery disease,
XX CC dysbetalipoproteinaemia or atherosclerosis; and for reducing the risk of
XX CC myocardial infarction or stroke; for breaking an embolus in the subject;
XX CC and also for treating angina. The synthetic apolipoprotein-E mimicking
XX CC polypeptide enhances binding of low-density lipoprotein (LDL) or very low
XX CC density lipoprotein (VLDL) to a cell and enhances degradation of LDL or
XX CC VLDL by a cell. This sequence represents a synthetic apolipoprotein-E
XX CC mimicking polypeptide of the invention.
XX SQ Sequence 18 AA;
AD034338 Length: 18 February 14, 2007 16:01 Type: P Check: 2998 ..
1 GRRFIGSIW RIFRAFYG
!!AA SEQUENCE 1.0
ID_ADO34341 standard; peptide; 18 AA.
XX AC ADO34341;
XX DT 12-AUG-2004 (first entry)
XX DE Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 129.
XX KW apolipoprotein-E mimicking polypeptide; antilipaeamic; cardiant;
XX KW vasotropic; antiarteriosclerotic; cerebroprotective; antianginal;
XX KW serum cholesterol; coronary artery disease; dysbetalipoproteinaemia;
XX OS Synthetic.
XX PN WO2004043403-A2.
XX PD 27-MAY-2004.
XX PF 13-NOV-2003; 2003WO-US036268.
XX PR 13-NOV-2002; 2002US-0425821P.
XX PA (UABR-) UAB RES FOUND.
XX PI Anantharamiah GM, Garber DW, Datta G;
XX DR WPI; 2004-411629/38.
XX PT Synthetic apolipoprotein-E mimicking polypeptide useful for treating
XX PT coronary artery disease, dysbetalipoproteinemia or atherosclerosis
XX PT comprises an amino acid sequence.
XX PS Claim 4; SEQ ID NO 115; 79pp; English.
XX CC The invention relates to a novel synthetic apolipoprotein-E mimicking
XX CC polypeptide. The invention further comprises an isolated nucleic acid
XX CC encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector,
XX CC a host cell, a recombinant cell or a transgenic, non-human subject
XX CC (including animal or plant) comprising the synthetic apolipoprotein-E
XX CC mimicking polypeptide encoding polynucleotide; a composition comprising
XX CC the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and
XX CC an monoclonal antibody that specifically binds to the synthetic
XX CC apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E
XX CC mimicking polypeptide has the following activities: antilipaeamic,
XX CC cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and
XX CC antianginal. The synthetic apolipoprotein-E mimicking polypeptide is
XX CC useful for reducing serum cholesterol in a subject (including a mammal
XX CC such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape,
XX CC chimpanzee or orangutan); for treating coronary artery disease,
XX CC dysbetalipoproteinaemia or atherosclerosis; and for reducing the risk of
XX CC myocardial infarction or stroke; for breaking an embolus in the subject;
XX CC and also for treating angina. The synthetic apolipoprotein-E mimicking
XX CC polypeptide enhances binding of low-density lipoprotein (LDL) or very low
XX CC density lipoprotein (VLDL) to a cell and enhances degradation of LDL or
XX CC VLDL by a cell. This sequence represents a synthetic apolipoprotein-E
XX CC mimicking polypeptide of the invention.
XX SQ Sequence 18 AA;
AD034338 Length: 18 February 14, 2007 16:01 Type: P Check: 2998 ..
1 GRRFLGSIW RIFRAFYG
!!AA SEQUENCE 1.0
ID_ADO34338 standard; peptide; 18 AA.
XX AC ADO34338;
XX DT 12-AUG-2004 (first entry)
XX DE Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 118.
XX KW apolipoprotein-E mimicking polypeptide; antilipaeamic; cardiant;
XX KW vasotropic; antiarteriosclerotic; cerebroprotective; antianginal;
XX KW serum cholesterol; coronary artery disease; dysbetalipoproteinaemia;
XX KW atherosclerosis; myocardial infarction; stroke; embolus; angina;
XX KW low-density lipoprotein; LDL; very low density lipoprotein; VLDL.
XX OS Synthetic.
XX PN WO2004043403-A2.
XX PD 27-MAY-2004.
XX PF 13-NOV-2003; 2003WO-US036268.
XX PR 13-NOV-2002; 2002US-0425821P.
XX PA (UABR-) UAB RES FOUND.
XX PI Anantharamiah GM, Garber DW, Datta G;
XX DR WPI; 2004-411629/38.
XX PT Synthetic apolipoprotein-E mimicking polypeptide useful for treating
XX PT coronary artery disease, dysbetalipoproteinemia or atherosclerosis
XX PT comprises an amino acid sequence.
XX PS Claim 4; SEQ ID NO 118; 79pp; English.
XX CC The invention relates to a novel synthetic apolipoprotein-E mimicking
XX CC polypeptide. The invention further comprises an isolated nucleic acid
XX CC encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector,
XX CC a host cell, a recombinant cell or a transgenic, non-human subject
XX CC (including animal or plant) comprising the synthetic apolipoprotein-E
XX CC mimicking polypeptide encoding polynucleotide; a composition comprising
XX CC the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and
XX CC an monoclonal antibody that specifically binds to the synthetic
XX CC apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E
XX CC mimicking polypeptide has the following activities: antilipaeamic,
XX CC cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and
XX CC antianginal. The synthetic apolipoprotein-E mimicking polypeptide is
XX CC useful for reducing serum cholesterol in a subject (including a mammal
XX CC such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape,
XX CC chimpanzee or orangutan); for treating coronary artery disease,
XX CC dysbetalipoproteinaemia or atherosclerosis; and for reducing the risk of
XX CC myocardial infarction or stroke; for breaking an embolus in the subject;
XX CC and also for treating angina. The synthetic apolipoprotein-E mimicking
XX CC polypeptide enhances binding of low-density lipoprotein (LDL) or very low
XX CC density lipoprotein (VLDL) to a cell and enhances degradation of LDL or
XX CC VLDL by a cell. This sequence represents a synthetic apolipoprotein-E
XX CC mimicking polypeptide of the invention.
XX SQ Sequence 18 AA;
AD034341 Length: 18 February 14, 2007 16:01 Type: P Check: 3028 ..
1 GRRFLGSEW RIFRAIYG
!!AA SEQUENCE 1.0
ID_ADO34352 standard; peptide; 18 AA.
XX AC ADO34352;
XX DT 12-AUG-2004 (first entry)
XX DE Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 129.
XX KW apolipoprotein-E mimicking polypeptide; antilipaeamic; cardiant;
XX KW vasotropic; antiarteriosclerotic; cerebroprotective; antianginal;
XX KW serum cholesterol; coronary artery disease; dysbetalipoproteinaemia;

```

KW atherosclerosis; myocardial infarction; stroke; embolus; angina;
 KW low-density lipoprotein; LDL; very low density lipoprotein; VLDL.
 XX Synthetic.
 OS
 XX WO2004043403-A2.
 PN
 XX
 XX
 PD 27-MAY-2004.
 XX
 XX 13-NOV-2003; 2003WO-US036268.
 PF
 XX
 XX 13-NOV-2002; 2002US-0425821P.
 PR
 XX
 PA (UABR-) UAB RES FOUND.
 XX
 XX Anantharamiah GM, Garber DW, Datta G;
 PI WPI; 2004-411629/38.
 DR
 XX Synthetic apolipoprotein-E mimicking polypeptide useful for treating
 XX coronary artery disease, dysbetalipoproteinemia or atherosclerosis
 PT comprises an amino acid sequence.
 PT
 XX
 XX Claim 4; SEQ ID NO 129; 79pp; English.
 PS
 XX The invention relates to a novel synthetic apolipoprotein-E mimicking
 CC polypeptide. The invention further comprises an isolated nucleic acid
 CC encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector,
 CC (including animal or plant) comprising the synthetic apolipoprotein-E
 CC mimicking polypeptide encoding polynucleotide; a composition comprising
 CC the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and
 CC an monoclonal antibody that specifically binds to the synthetic
 CC apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E
 CC mimicking polypeptide has the following activities: antilipemic,
 CC cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and
 CC antianginal. The synthetic apolipoprotein-E mimicking polypeptide is
 CC useful for reducing serum cholesterol in a subject (including a mammal
 CC such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape,
 CC chimpanzee or orangutan); for treating coronary artery disease,
 CC dysbetalipoproteinemia or atherosclerosis; and for reducing the risk of
 CC myocardial infarction or stroke; for breaking an embolus in the subject;
 CC and also for treating angina. The synthetic apolipoprotein-E mimicking
 CC polypeptide enhances binding of low-density lipoprotein (LDL) or very low
 CC density lipoprotein (VLDL) to a cell and enhances degradation of LDL or
 CC VLDL by a cell. This sequence represents a synthetic apolipoprotein-E
 CC mimicking polypeptide of the invention.
 XX
 SQ Sequence 18 AA;
 AD034352 Length: 18 February 14, 2007 16:01 Type: P Check: 3076 ..
 1 GRRFLGSLW RFLRAFVG
 !!AA SEQUENCE 1.0
 ID_ADO34379 standard; peptide; 14 AA.
 XX
 AC ADO34379;
 XX
 XX 12-AUG-2004 (first entry)
 DT
 XX Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 156.
 DE
 XX apolipoprotein-E mimicking polypeptide; antilipemic; cardiant;
 KW vasotropic; antiarteriosclerotic; cerebroprotective; antianginal;
 KW serum cholesterol; coronary artery disease; dysbetalipoproteinemia;
 KW atherosclerosis; myocardial infarction; stroke; embolus; angina;
 KW low-density lipoprotein; LDL; very low density lipoprotein; VLDL.
 XX
 OS Synthetic.
 OS
 XX WO2004043403-A2.
 PN
 XX

PD 27-MAY-2004.
 XX
 PF 13-NOV-2003; 2003WO-US036268.
 XX
 PR 13-NOV-2002; 2002US-0425821P.
 XX
 PA (UABR-) UAB RES FOUND.
 XX
 XX Anantharamiah GM, Garber DW, Datta G;
 PI WPI; 2004-411629/38.
 DR
 XX Synthetic apolipoprotein-E mimicking polypeptide useful for treating
 XX coronary artery disease, dysbetalipoproteinemia or atherosclerosis
 PT comprises an amino acid sequence.
 PT
 XX
 XX Claim 4; SEQ ID NO 156; 79pp; English.
 PS
 XX The invention relates to a novel synthetic apolipoprotein-E mimicking
 CC polypeptide. The invention further comprises an isolated nucleic acid
 CC encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector,
 CC (including animal or plant) comprising the synthetic apolipoprotein-E
 CC mimicking polypeptide encoding polynucleotide; a composition comprising
 CC the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and
 CC an monoclonal antibody that specifically binds to the synthetic
 CC apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E
 CC mimicking polypeptide has the following activities: antilipemic,
 CC cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and
 CC antianginal. The synthetic apolipoprotein-E mimicking polypeptide is
 CC useful for reducing serum cholesterol in a subject (including a mammal
 CC such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape,
 CC chimpanzee or orangutan); for treating coronary artery disease,
 CC dysbetalipoproteinemia or atherosclerosis; and for reducing the risk of
 CC myocardial infarction or stroke; for breaking an embolus in the subject;
 CC and also for treating angina. The synthetic apolipoprotein-E mimicking
 CC polypeptide enhances binding of low-density lipoprotein (LDL) or very low
 CC density lipoprotein (VLDL) to a cell and enhances degradation of LDL or
 CC VLDL by a cell. This sequence represents a synthetic apolipoprotein-E
 CC mimicking polypeptide of the invention.
 XX
 SQ Sequence 14 AA;
 AD034379 Length: 14 February 14, 2007 16:01 Type: P Check: 8208 ..
 1 GLRRFYGSIW RFIR
 !!AA SEQUENCE 1.0
 ID_ADO34380 standard; peptide; 14 AA.
 XX
 AC ADO34380;
 XX
 XX 12-AUG-2004 (first entry)
 DT
 XX Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 157.
 DE
 XX apolipoprotein-E mimicking polypeptide; antilipemic; cardiant;
 KW vasotropic; antiarteriosclerotic; cerebroprotective; antianginal;
 KW serum cholesterol; coronary artery disease; dysbetalipoproteinemia;
 KW atherosclerosis; myocardial infarction; stroke; embolus; angina;
 KW low-density lipoprotein; LDL; very low density lipoprotein; VLDL.
 XX
 OS Synthetic.
 OS
 XX WO2004043403-A2.
 PN
 XX 27-MAY-2004.
 PD
 XX
 XX 13-NOV-2003; 2003WO-US036268.
 PF
 XX
 XX 13-NOV-2002; 2002US-0425821P.
 PR
 XX
 PA (UABR-) UAB RES FOUND.
 XX

XX
PI Anantharamiah GM, Garber DW, Datta G;
XX
DR WPI; 2004-411629/38.
XX
XX Synthetic apolipoprotein-E mimicking polypeptide useful for treating
PT coronary artery disease, dysbetalipoproteinemia or atherosclerosis
PT comprises an amino acid sequence.
XX
XX Claim 4; SEQ ID NO 157; 79pp; English.
XX
XX The invention relates to a novel synthetic apolipoprotein-E mimicking
CC polypeptide. The invention further comprises an isolated nucleic acid
CC encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector,
CC (including animal or plant) comprising the synthetic apolipoprotein-E
CC mimicking polypeptide encoding polynucleotide; a composition comprising
CC the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and
CC an monoclonal antibody that specifically binds to the synthetic
CC apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E
CC mimicking polypeptide has the following activities: antilipemic,
CC cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and
CC antilipemic. The synthetic apolipoprotein-E mimicking polypeptide is
CC useful for reducing serum cholesterol in a subject (including a mammal
CC such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape,
CC chimpanzee or orangutan); for treating coronary artery disease,
CC dysbetalipoproteinemia or atherosclerosis; and for reducing the risk of
CC myocardial infarction or stroke; for breaking an embolus in the subject;
CC and also for treating angina. The synthetic apolipoprotein-E mimicking
CC polypeptide enhances binding of low-density lipoprotein (LDL) or very low
CC density lipoprotein (VLDL) to a cell and enhances degradation of LDL or
CC VLDL by a cell. This sequence represents a synthetic apolipoprotein-E
CC mimicking polypeptide of the invention.
XX
XX Sequence 14 AA;
XX
AD034380 Length: 14 February 14, 2007 16:01 Type: P Check: 8229 ..
1 GIRRYFGLSLW RFIR

!!AA_SEQUENCE 1.0
ID_ADO34383 standard; peptide; 14 AA.
XX
AC ADO34383;
XX
DT 12-AUG-2004 (first entry)
XX
XX Synthetic apolipoprotein-E mimicking peptide, SEQ ID NO 160.
XX
XX apolipoprotein-E mimicking polypeptide; antilipemic; cardiant;
XX vasotropic; antiarteriosclerotic; cerebroprotective; antilipemic;
XX serum cholesterol; coronary artery disease; dysbetalipoproteinemia;
XX atherosclerosis; myocardial infarction; stroke; embolus; angina;
XX low-density lipoprotein; LDL; very low density lipoprotein; VLDL.
XX
OS Synthetic.
XX
XX WO2004043403-A2.
XX
PD 27-MAY-2004.
XX
XX 13-NOV-2003; 2003WO-US036268.
XX
XX 13-NOV-2002; 2002US-0425821P.
XX
XX (UABR-) UAB RES FOUND.
XX
XX Anantharamiah GM, Garber DW, Datta G;
XX
XX WPI; 2004-411629/38.
XX
XX Synthetic apolipoprotein-E mimicking polypeptide useful for treating
PT coronary artery disease, dysbetalipoproteinemia or atherosclerosis

PT comprises an amino acid sequence.
XX
XX Claim 4; SEQ ID NO 160; 79pp; English.
XX
XX The invention relates to a novel synthetic apolipoprotein-E mimicking
CC polypeptide. The invention further comprises an isolated nucleic acid
CC encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector,
CC a host cell, a recombinant cell or a transgenic, non-human subject
CC (including animal or plant) comprising the synthetic apolipoprotein-E
CC mimicking polypeptide encoding polynucleotide; a composition comprising
CC the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and
CC an monoclonal antibody that specifically binds to the synthetic
CC apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E
CC mimicking polypeptide has the following activities: antilipemic,
CC cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and
CC antilipemic. The synthetic apolipoprotein-E mimicking polypeptide is
CC useful for reducing serum cholesterol in a subject (including a mammal
CC such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape,
CC chimpanzee or orangutan); for treating coronary artery disease,
CC dysbetalipoproteinemia or atherosclerosis; and for reducing the risk of
CC myocardial infarction or stroke; for breaking an embolus in the subject;
CC and also for treating angina. The synthetic apolipoprotein-E mimicking
CC polypeptide enhances binding of low-density lipoprotein (LDL) or very low
CC density lipoprotein (VLDL) to a cell and enhances degradation of LDL or
CC VLDL by a cell. This sequence represents a synthetic apolipoprotein-E
CC mimicking polypeptide of the invention.
XX
XX Sequence 14 AA;
XX
AD034383 Length: 14 February 14, 2007 16:01 Type: P Check: 8210 ..
1 GIRRYFGLSLW RFIR

!!AA_SEQUENCE 1.0
ID_ADO34390 standard; peptide; 14 AA.
XX
AC ADO34390;
XX
DT 12-AUG-2004 (first entry)
XX
XX Synthetic apolipoprotein-E mimicking peptide, SEQ ID NO 167.
XX
XX apolipoprotein-E mimicking polypeptide; antilipemic; cardiant;
XX vasotropic; antiarteriosclerotic; cerebroprotective; antilipemic;
XX serum cholesterol; coronary artery disease; dysbetalipoproteinemia;
XX atherosclerosis; myocardial infarction; stroke; embolus; angina;
XX low-density lipoprotein; LDL; very low density lipoprotein; VLDL.
XX
OS Synthetic.
XX
XX WO2004043403-A2.
XX
PD 27-MAY-2004.
XX
XX 13-NOV-2003; 2003WO-US036268.
XX
XX 13-NOV-2002; 2002US-0425821P.
XX
XX (UABR-) UAB RES FOUND.
XX
XX Anantharamiah GM, Garber DW, Datta G;
XX
XX WPI; 2004-411629/38.
XX
XX Synthetic apolipoprotein-E mimicking polypeptide useful for treating
PT coronary artery disease, dysbetalipoproteinemia or atherosclerosis
PT comprises an amino acid sequence.
XX
XX Claim 4; SEQ ID NO 167; 79pp; English.
XX
XX The invention relates to a novel synthetic apolipoprotein-E mimicking
CC polypeptide. The invention further comprises an isolated nucleic acid
CC encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector,
CC (including animal or plant) comprising the synthetic apolipoprotein-E
CC mimicking polypeptide encoding polynucleotide; a composition comprising
CC the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and
CC an monoclonal antibody that specifically binds to the synthetic
CC apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E
CC mimicking polypeptide has the following activities: antilipemic,
CC cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and
CC antilipemic. The synthetic apolipoprotein-E mimicking polypeptide is
CC useful for reducing serum cholesterol in a subject (including a mammal
CC such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape,
CC chimpanzee or orangutan); for treating coronary artery disease,
CC dysbetalipoproteinemia or atherosclerosis; and for reducing the risk of
CC myocardial infarction or stroke; for breaking an embolus in the subject;
CC and also for treating angina. The synthetic apolipoprotein-E mimicking
CC polypeptide enhances binding of low-density lipoprotein (LDL) or very low
CC density lipoprotein (VLDL) to a cell and enhances degradation of LDL or
CC VLDL by a cell. This sequence represents a synthetic apolipoprotein-E
CC mimicking polypeptide of the invention.

CC a host cell, a recombinant cell or a transgenic, non-human subject
CC (including animal or plant) comprising the synthetic apolipoprotein-E
CC mimicking polypeptide encoding polynucleotide; a composition comprising
CC the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and
CC an monoclonal antibody that specifically binds to the synthetic
CC apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E
CC mimicking polypeptide has the following activities: antilipaeamic,
CC cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and
CC useful for reducing serum cholesterol in a subject (including a mammal,
CC such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape,
CC chimpanzee or orangutan); for treating coronary artery disease,
CC dysbetalipoproteinemia or atherosclerosis; and for reducing the risk of
CC myocardial infarction or stroke; for breaking an embolus in the subject;
CC and also for treating angina. The synthetic apolipoprotein-E mimicking
CC polypeptide enhances binding of low-density lipoprotein (LDL) or very low
CC density lipoprotein (VLDL) to a cell and enhances degradation of LDL or
CC VLDL by a cell. This sequence represents a synthetic apolipoprotein-E
CC mimicking polypeptide of the invention.
XX
SQ Sequence 14 AA;

AD034390 Length: 14 February 14, 2007 16:01 Type: P Check: 8226 ..

1 GFRFLGSIW RFIR

!!AA SEQUENCE 1.0
ID AD034228 standard; peptide; 18 AA.
XX
AC AD034228;
XX
DT 12-AUG-2004 (first entry)
XX
DE Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 5.
XX
KW apolipoprotein-E mimicking polypeptide; antilipaeamic; cardiant;
KW vasotropic; antiarteriosclerotic; cerebroprotective; antianginal;
KW serum cholesterol; coronary artery disease; dysbetalipoproteinemia;
KW atherosclerosis; myocardial infarction; stroke; embolus; angina;
KW low-density lipoprotein; LDL; very low density lipoprotein; VLDL.
XX
OS Synthetic.
XX
PN WO2004043403-A2.
XX
PD 27-MAY-2004.

13-NOV-2003; 2003WO-US036268.

13-NOV-2002; 2002US-0425821P.

(UABR-) UAB RES FOUND.

Anantharamiah GM, Garber DW, Datta G;

WPI; 2004-411629/38.

Synthetic apolipoprotein-E mimicking polypeptide useful for treating
PT coronary artery disease, dysbetalipoproteinemia or atherosclerosis
PT comprises an amino acid sequence.

Claim 4; SEQ ID NO 5; 79pp; English.

CC The invention relates to a novel synthetic apolipoprotein-E mimicking
CC polypeptide. The invention further comprises an isolated nucleic acid
CC encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector,
CC a host cell, a recombinant cell or a transgenic, non-human subject
CC (including animal or plant) comprising the synthetic apolipoprotein-E
CC mimicking polypeptide encoding polynucleotide; a composition comprising
CC the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and
CC an monoclonal antibody that specifically binds to the synthetic
CC apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E
CC mimicking polypeptide has the following activities: antilipaeamic,

CC cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and
CC antianginal. The synthetic apolipoprotein-E mimicking polypeptide is
CC useful for reducing serum cholesterol in a subject (including a mammal
CC such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape,
CC chimpanzee or orangutan); for treating coronary artery disease,
CC dysbetalipoproteinemia or atherosclerosis; and for reducing the risk of
CC myocardial infarction or stroke; for breaking an embolus in the subject;
CC and also for treating angina. The synthetic apolipoprotein-E mimicking
CC polypeptide enhances binding of low-density lipoprotein (LDL) or very low
CC density lipoprotein (VLDL) to a cell and enhances degradation of LDL or
CC VLDL by a cell. This sequence represents a synthetic apolipoprotein-E
CC mimicking polypeptide of the invention.
XX
SQ Sequence 18 AA;

AD034228 Length: 18 February 14, 2007 16:01 Type: P Check: 3010 ..

1 GIRRFLGSIW RFIRAFYG

!!AA SEQUENCE 1.0
ID AD034236 standard; peptide; 18 AA.
XX
AC AD034236;
XX
DT 12-AUG-2004 (first entry)

Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 13.

apolipoprotein-E mimicking polypeptide; antilipaeamic; cardiant;
KW vasotropic; antiarteriosclerotic; cerebroprotective; antianginal;
KW serum cholesterol; coronary artery disease; dysbetalipoproteinemia;
KW atherosclerosis; myocardial infarction; stroke; embolus; angina;
KW low-density lipoprotein; LDL; very low density lipoprotein; VLDL.
XX
OS Synthetic.
XX
PN WO2004043403-A2.
XX
PD 27-MAY-2004.

13-NOV-2003; 2003WO-US036268.

13-NOV-2002; 2002US-0425821P.

(UABR-) UAB RES FOUND.

Anantharamiah GM, Garber DW, Datta G;

WPI; 2004-411629/38.

Synthetic apolipoprotein-E mimicking polypeptide useful for treating
PT coronary artery disease, dysbetalipoproteinemia or atherosclerosis
PT comprises an amino acid sequence.

Claim 4; SEQ ID NO 13; 79pp; English.

CC The invention relates to a novel synthetic apolipoprotein-E mimicking
CC polypeptide. The invention further comprises an isolated nucleic acid
CC encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector,
CC a host cell, a recombinant cell or a transgenic, non-human subject
CC (including animal or plant) comprising the synthetic apolipoprotein-E
CC mimicking polypeptide encoding polynucleotide; a composition comprising
CC the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and
CC an monoclonal antibody that specifically binds to the synthetic
CC apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E
CC mimicking polypeptide has the following activities: antilipaeamic,
CC cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and
CC antianginal. The synthetic apolipoprotein-E mimicking polypeptide is
CC useful for reducing serum cholesterol in a subject (including a mammal
CC such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape,
CC chimpanzee or orangutan); for treating coronary artery disease,
CC dysbetalipoproteinemia or atherosclerosis; and for reducing the risk of
CC myocardial infarction or stroke; for breaking an embolus in the subject;

CC and also for treating angina. The synthetic apolipoprotein-E mimicking
 CC polypeptide enhances binding of low-density lipoprotein (LDL) or very low
 CC density lipoprotein (VLDL) to a cell and enhances degradation of LDL or
 CC VLDL by a cell. This sequence represents a synthetic apolipoprotein-E
 CC mimicking polypeptide of the invention.

XX SQ Sequence 18 AA;

AD034236 Length: 18 February 14, 2007 16:01 Type: P Check: 3010

1 GIRRFSGSIW RFRAFYG

!!AA SEQUENCE 1.0
 ID ADO34340 standard; peptide; 18 AA.

XX AC ADO34340;

DT 12-AUG-2004 (first entry)

XX Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 117.

XX apolipoprotein-E mimicking polypeptide; antilipaeamic; cardiant;
 KW vasotropic; antiarteriosclerotic; cerebroprotective; antianginal;
 KW serum cholesterol; coronary artery disease; dysbetalipoproteinaemia;
 KW atherosclerosis; myocardial infarction; stroke; embolus; angina;
 KW low-density lipoprotein; LDL; very low density lipoprotein; VLDL.

XX OS Synthetic.

XX WO2004043403-A2.

XX PD 27-MAY-2004.

XX PF 13-NOV-2003; 2003WO-US036268.

XX PR 13-NOV-2002; 2002US-0425821P.

XX PA (UABR-) UAB RES FOUND.

XX PI Anantharamiah GM, Garber DW, Datta G;

XX WPI; 2004-411629/38.

XX Synthetic apolipoprotein-E mimicking polypeptide useful for treating
 PT coronary artery disease, dysbetalipoproteinemia or atherosclerosis
 PT comprises an amino acid sequence.

XX Claim 4; SEQ ID NO 117; 79pp; English.

XX The invention relates to a novel synthetic apolipoprotein-E mimicking
 CC polypeptide. The invention further comprises an isolated nucleic acid
 CC encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector,
 CC a host cell, a recombinant cell or a transgenic, non-human subject
 CC (including animal or plant) comprising the synthetic apolipoprotein-E
 CC mimicking polypeptide encoding polynucleotide; a composition comprising
 CC the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and
 CC an monoclonal antibody that specifically binds to the synthetic
 CC apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E
 CC mimicking polypeptide has the following activities: antilipaeamic,
 CC cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and
 CC antianginal. The synthetic apolipoprotein-E mimicking polypeptide is
 CC useful for reducing serum cholesterol in a subject (including a mammal
 CC such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape,
 CC chimpanzee or orangutan); for treating coronary artery disease,
 CC dysbetalipoproteinaemia or atherosclerosis; and for reducing the risk of
 CC myocardial infarction or stroke; for breaking an embolus in the subject;
 CC and also for treating angina. The synthetic apolipoprotein-E mimicking
 CC polypeptide enhances binding of low-density lipoprotein (LDL) or very low
 CC density lipoprotein (VLDL) to a cell and enhances degradation of LDL or
 CC VLDL by a cell. This sequence represents a synthetic apolipoprotein-E
 CC mimicking polypeptide of the invention.

XX SQ Sequence 18 AA;

AD034340 Length: 18 February 14, 2007 16:01 Type: P Check: 3031

1 GIRRFSGSIW RFLAFYG

!!AA SEQUENCE 1.0

XX ID ADO34356 standard; peptide; 14 AA.

XX AC ADO34356;

XX DT 12-AUG-2004 (first entry)

XX Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 133.

XX apolipoprotein-E mimicking polypeptide; antilipaeamic; cardiant;
 KW vasotropic; antiarteriosclerotic; cerebroprotective; antianginal;
 KW serum cholesterol; coronary artery disease; dysbetalipoproteinaemia;
 KW atherosclerosis; myocardial infarction; stroke; embolus; angina;
 KW low-density lipoprotein; LDL; very low density lipoprotein; VLDL.

XX OS Synthetic.

XX WO2004043403-A2.

XX PD 27-MAY-2004.

XX PF 13-NOV-2003; 2003WO-US036268.

XX PR 13-NOV-2002; 2002US-0425821P.

XX PA (UABR-) UAB RES FOUND.

XX PI Anantharamiah GM, Garber DW, Datta G;

XX WPI; 2004-411629/38.

XX Synthetic apolipoprotein-E mimicking polypeptide useful for treating
 PT coronary artery disease, dysbetalipoproteinemia or atherosclerosis
 PT comprises an amino acid sequence.

XX Claim 4; SEQ ID NO 133; 79pp; English.

XX The invention relates to a novel synthetic apolipoprotein-E mimicking
 CC polypeptide. The invention further comprises an isolated nucleic acid
 CC encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector,
 CC a host cell, a recombinant cell or a transgenic, non-human subject
 CC (including animal or plant) comprising the synthetic apolipoprotein-E
 CC mimicking polypeptide encoding polynucleotide; a composition comprising
 CC the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and
 CC an monoclonal antibody that specifically binds to the synthetic
 CC apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E
 CC mimicking polypeptide has the following activities: antilipaeamic,
 CC cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and
 CC antianginal. The synthetic apolipoprotein-E mimicking polypeptide is
 CC useful for reducing serum cholesterol in a subject (including a mammal
 CC such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape,
 CC chimpanzee or orangutan); for treating coronary artery disease,
 CC dysbetalipoproteinaemia or atherosclerosis; and for reducing the risk of
 CC myocardial infarction or stroke; for breaking an embolus in the subject;
 CC and also for treating angina. The synthetic apolipoprotein-E mimicking
 CC polypeptide enhances binding of low-density lipoprotein (LDL) or very low
 CC density lipoprotein (VLDL) to a cell and enhances degradation of LDL or
 CC VLDL by a cell. This sequence represents a synthetic apolipoprotein-E
 CC mimicking polypeptide of the invention.

XX SQ Sequence 14 AA;

AD034356 Length: 14 February 14, 2007 16:01 Type: P Check: 8202

1 GIRRFSGSIW RFRIF

!!AA SEQUENCE 1.0

ID ADO34364 standard; peptide; 14 AA.

XX AC ADO34364;
 XX DT 12-AUG-2004 (first entry)
 XX DE Synthetic apolipoprotein-E mimicking peptide, SEQ ID NO 141.
 XX OS
 KW apolipoprotein-E mimicking polypeptide; antilipaeamic; cardiant;
 KW vasotropic; antiarteriosclerotic; cerebroprotective; antianginal;
 KW serum cholesterol; coronary artery disease; dysbetalipoproteinaemia;
 KW atherosclerosis; myocardial infarction; stroke; embolus; angina;
 KW low-density lipoprotein; LDL; very low density lipoprotein; VLDL.
 XX OS
 XX Synthetic.
 XX WO2004043403-A2.
 XX PN 27-MAY-2004.
 XX PD
 XX PF 13-NOV-2003; 2003WO-US036268.
 XX PR 13-NOV-2002; 2002US-0425821P.
 XX PA (UABR-) UAB RES FOUND.
 XX PI Anantharamiah GM, Garber DW, Datta G;
 XX DR WPI; 2004-411629/38.
 XX DT Synthetic apolipoprotein-E mimicking polypeptide useful for treating
 PT coronary artery disease, dysbetalipoproteinemia or atherosclerosis
 PT comprises an amino acid sequence.
 XX PS Claim 4; SEQ ID NO 141; 79pp; English.
 XX CC The invention relates to a novel synthetic apolipoprotein-E mimicking
 CC polypeptide. The invention further comprises an isolated nucleic acid
 CC encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector,
 CC a host cell, a recombinant cell or a transgenic, non-human subject
 CC (including animal or plant) comprising the synthetic apolipoprotein-E
 CC mimicking polypeptide encoding polynucleotide; a composition comprising
 CC the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and
 CC an monoclonal antibody that specifically binds to the synthetic
 CC apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E
 CC mimicking polypeptide has the following activities: antilipaeamic,
 CC cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and
 CC antianginal. The synthetic apolipoprotein-E mimicking polypeptide is
 CC useful for reducing serum cholesterol in a subject (including a mammal
 CC such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape,
 CC chimpanzee or orangutan); for treating coronary artery disease,
 CC dysbetalipoproteinaemia or atherosclerosis; and for reducing the risk of
 CC myocardial infarction or stroke; for breaking an embolus in the subject;
 CC and also for treating angina. The synthetic apolipoprotein-E mimicking
 CC polypeptide enhances binding of low-density lipoprotein (LDL) or very low
 CC density lipoprotein (VLDL) to a cell and enhances degradation of LDL or
 CC VLDL by a cell. This sequence represents a synthetic apolipoprotein-E
 CC mimicking polypeptide of the invention.
 XX SQ Sequence 14 AA;
 ADO34364 Length: 14 February 14, 2007 16:01 Type: P Check: 8241 ..
 1 GRRFVGSIW RFLR
 !!AA SEQUENCE 1.0
 ID ADO34419 standard; peptide; 14 AA.
 XX AC ADO34419;
 XX DT 12-AUG-2004 (first entry)
 XX DE Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 196.
 XX OS

KW apolipoprotein-E mimicking polypeptide; antilipaeamic; cardiant;
 KW vasotropic; antiarteriosclerotic; cerebroprotective; antianginal;
 KW serum cholesterol; coronary artery disease; dysbetalipoproteinaemia;
 KW atherosclerosis; myocardial infarction; stroke; embolus; angina;
 KW low-density lipoprotein; LDL; very low density lipoprotein; VLDL.
 XX OS
 XX Synthetic.
 XX WO2004043403-A2.
 XX PN 27-MAY-2004.
 XX PD
 XX PF 13-NOV-2003; 2003WO-US036268.
 XX PR 13-NOV-2002; 2002US-0425821P.
 XX PA (UABR-) UAB RES FOUND.
 XX PI Anantharamiah GM, Garber DW, Datta G;
 XX DR WPI; 2004-411629/38.
 XX DT Synthetic apolipoprotein-E mimicking polypeptide useful for treating
 PT coronary artery disease, dysbetalipoproteinemia or atherosclerosis
 PT comprises an amino acid sequence.
 XX PS Claim 4; SEQ ID NO 196; 79pp; English.
 XX CC The invention relates to a novel synthetic apolipoprotein-E mimicking
 CC polypeptide. The invention further comprises an isolated nucleic acid
 CC encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector,
 CC a host cell, a recombinant cell or a transgenic, non-human subject
 CC (including animal or plant) comprising the synthetic apolipoprotein-E
 CC mimicking polypeptide encoding polynucleotide; a composition comprising
 CC the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and
 CC an monoclonal antibody that specifically binds to the synthetic
 CC apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E
 CC mimicking polypeptide has the following activities: antilipaeamic,
 CC cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and
 CC antianginal. The synthetic apolipoprotein-E mimicking polypeptide is
 CC useful for reducing serum cholesterol in a subject (including a mammal
 CC such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape,
 CC chimpanzee or orangutan); for treating coronary artery disease,
 CC dysbetalipoproteinaemia or atherosclerosis; and for reducing the risk of
 CC myocardial infarction or stroke; for breaking an embolus in the subject;
 CC and also for treating angina. The synthetic apolipoprotein-E mimicking
 CC polypeptide enhances binding of low-density lipoprotein (LDL) or very low
 CC density lipoprotein (VLDL) to a cell and enhances degradation of LDL or
 CC VLDL by a cell. This sequence represents a synthetic apolipoprotein-E
 CC mimicking polypeptide of the invention.
 XX SQ Sequence 14 AA;
 ADO34419 Length: 14 February 14, 2007 16:01 Type: P Check: 8198 ..
 1 GRRFVSGWLW RFLR
 !!AA SEQUENCE 1.0
 ID ADO34227 standard; peptide; 18 AA.
 XX AC ADO34227;
 XX DT 12-AUG-2004 (first entry)
 XX DE Synthetic apolipoprotein-E mimicking related R18L linear peptide.
 XX OS
 KW apolipoprotein-E mimicking polypeptide; antilipaeamic; cardiant;
 KW vasotropic; antiarteriosclerotic; cerebroprotective; antianginal;
 KW serum cholesterol; coronary artery disease; dysbetalipoproteinaemia;
 KW atherosclerosis; myocardial infarction; stroke; embolus; angina;
 KW low-density lipoprotein; LDL; very low density lipoprotein; VLDL.
 XX OS
 XX Synthetic.

```

XX PN WO2004043403-A2.
XX PD 27-MAY-2004.
XX PF 13-NOV-2003; 2003WO-US036268.
XX PR 13-NOV-2002; 2002US-0425821P.
XX PA (UABR-) UAB RES FOUND.
XX PI Anantharamiah GM, Garber DW, Datta G;
XX PS WPI; 2004-411629/38.
XX DR
XX CC Synthetic apolipoprotein-E mimicking polypeptide useful for treating
XX PT coronary artery disease, dysbetalipoproteinemia or atherosclerosis
XX PT comprises an amino acid sequence.
XX CC
XX PS Claim 4; SEQ ID NO 4; 79pp; English.
XX CC The invention relates to a novel synthetic apolipoprotein-E mimicking
XX CC polypeptide. The invention further comprises an isolated nucleic acid
XX CC encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector,
XX CC a host cell, a recombinant cell or a transgenic, non-human subject
XX CC (including animal or plant) comprising the synthetic apolipoprotein-E
XX CC mimicking polypeptide encoding polynucleotide; a composition comprising
XX CC the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and
XX CC an monoclonal antibody that specifically binds to the synthetic
XX CC apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E
XX CC mimicking polypeptide has the following activities: antilipemic,
XX CC cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and
XX CC antidiabetic. The synthetic apolipoprotein-E mimicking polypeptide is
XX CC useful for reducing serum cholesterol in a subject (including a mammal
XX CC such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape,
XX CC chimpanzee or orangutan); for treating coronary artery disease,
XX CC dysbetalipoproteinemia or atherosclerosis; and for reducing the risk of
XX CC myocardial infarction or stroke; for breaking an embolus in the subject;
XX CC and also for treating angina. The synthetic apolipoprotein-E mimicking
XX CC polypeptide enhances binding of low-density lipoprotein (LDL) or very low
XX CC density lipoprotein (VLDL) to a cell and enhances degradation of LDL or
XX CC VLDL by a cell. This sequence represents a synthetic apolipoprotein-E
XX CC mimicking polypeptide of the invention.
XX SQ Sequence 18 AA;
AD034227 Length: 18 February 14, 2007 16:01 Type: P Check: 2959 ..
1 GRRFLGSIW RFIRAFVG
!!AA SEQUENCE 1.0
ID -AD034344 standard; peptide; 18 AA.
XX AC AD034344;
XX XX
XX DT 12-AUG-2004 (first entry)
XX DE Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 121.
XX OS
XX KW apolipoprotein-E mimicking polypeptide; antilipemic; cardiant;
XX KW vasotropic; antiarteriosclerotic; cerebroprotective; antidiabetic;
XX KW serum cholesterol; coronary artery disease; dysbetalipoproteinemia;
XX KW atherosclerosis; myocardial infarction; stroke; embolus; angina;
XX KW low-density lipoprotein; LDL; very low density lipoprotein; VLDL.
XX OS Synthetic.
XX WO2004043403-A2.
XX PD 27-MAY-2004.
XX PF 13-NOV-2003; 2003WO-US036268.
XX PR
XX PA (UABR-) UAB RES FOUND.
XX PI Anantharamiah GM, Garber DW, Datta G;
XX PS WPI; 2004-411629/38.
XX DR
XX CC Synthetic apolipoprotein-E mimicking polypeptide useful for treating
XX PT coronary artery disease, dysbetalipoproteinemia or atherosclerosis
XX PT comprises an amino acid sequence.
XX CC
XX PS Claim 4; SEQ ID NO 4; 79pp; English.
XX CC The invention relates to a novel synthetic apolipoprotein-E mimicking
XX CC polypeptide. The invention further comprises an isolated nucleic acid
XX CC encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector,
XX CC a host cell, a recombinant cell or a transgenic, non-human subject
XX CC (including animal or plant) comprising the synthetic apolipoprotein-E
XX CC mimicking polypeptide encoding polynucleotide; a composition comprising
XX CC the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and
XX CC an monoclonal antibody that specifically binds to the synthetic
XX CC apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E
XX CC mimicking polypeptide has the following activities: antilipemic,
XX CC cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and
XX CC antidiabetic. The synthetic apolipoprotein-E mimicking polypeptide is
XX CC useful for reducing serum cholesterol in a subject (including a mammal
XX CC such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape,
XX CC chimpanzee or orangutan); for treating coronary artery disease,
XX CC dysbetalipoproteinemia or atherosclerosis; and for reducing the risk of
XX CC myocardial infarction or stroke; for breaking an embolus in the subject;
XX CC and also for treating angina. The synthetic apolipoprotein-E mimicking
XX CC polypeptide enhances binding of low-density lipoprotein (LDL) or very low
XX CC density lipoprotein (VLDL) to a cell and enhances degradation of LDL or
XX CC VLDL by a cell. This sequence represents a synthetic apolipoprotein-E
XX CC mimicking polypeptide of the invention.
XX SQ Sequence 18 AA;
AD034344 Length: 18 February 14, 2007 16:01 Type: P Check: 2867 ..
1 GRRFYGSIW RFIRAPLG
!!AA SEQUENCE 1.0
ID -AD034372 standard; peptide; 14 AA.
XX AC AD034372;
XX XX
XX DT 12-AUG-2004 (first entry)
XX DE Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 149.
XX OS
XX KW apolipoprotein-E mimicking polypeptide; antilipemic; cardiant;
XX KW vasotropic; antiarteriosclerotic; cerebroprotective; antidiabetic;
XX KW serum cholesterol; coronary artery disease; dysbetalipoproteinemia;
XX KW atherosclerosis; myocardial infarction; stroke; embolus; angina;
XX KW low-density lipoprotein; LDL; very low density lipoprotein; VLDL.
XX OS Synthetic.
XX WO2004043403-A2.
XX PD 27-MAY-2004.
XX PF 13-NOV-2003; 2003WO-US036268.
XX PR 13-NOV-2002; 2002US-0425821P.
XX PA (UABR-) UAB RES FOUND.
XX PI Anantharamiah GM, Garber DW, Datta G;
XX PS WPI; 2004-411629/38.
XX DR

```

```

PR 13-NOV-2002; 2002US-0425821P.
XX (UABR-) UAB RES FOUND.
XX ANantharamiah GM, Garber DW, Datta G;
XX WPI; 2004-411629/38.
XX Synthetic apolipoprotein-E mimicking polypeptide useful for treating
XX PT coronary artery disease, dysbetalipoproteinemia or atherosclerosis
XX PT comprises an amino acid sequence.
XX PS Claim 4; SEQ ID NO 121; 79pp; English.
XX CC The invention relates to a novel synthetic apolipoprotein-E mimicking
XX CC polypeptide. The invention further comprises an isolated nucleic acid
XX CC encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector,
XX CC a host cell, a recombinant cell or a transgenic, non-human subject
XX CC (including animal or plant) comprising the synthetic apolipoprotein-E
XX CC mimicking polypeptide encoding polynucleotide; a composition comprising
XX CC the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and
XX CC an monoclonal antibody that specifically binds to the synthetic
XX CC apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E
XX CC mimicking polypeptide has the following activities: antilipemic,
XX CC cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and
XX CC antidiabetic. The synthetic apolipoprotein-E mimicking polypeptide is
XX CC useful for reducing serum cholesterol in a subject (including a mammal
XX CC such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape,
XX CC chimpanzee or orangutan); for treating coronary artery disease,
XX CC dysbetalipoproteinemia or atherosclerosis; and for reducing the risk of
XX CC myocardial infarction or stroke; for breaking an embolus in the subject;
XX CC and also for treating angina. The synthetic apolipoprotein-E mimicking
XX CC polypeptide enhances binding of low-density lipoprotein (LDL) or very low
XX CC density lipoprotein (VLDL) to a cell and enhances degradation of LDL or
XX CC VLDL by a cell. This sequence represents a synthetic apolipoprotein-E
XX CC mimicking polypeptide of the invention.
XX SQ Sequence 18 AA;
AD034344 Length: 18 February 14, 2007 16:01 Type: P Check: 2867 ..
1 GRRFYGSIW RFIRAPLG
!!AA SEQUENCE 1.0
ID -AD034372 standard; peptide; 14 AA.
XX AC AD034372;
XX XX
XX DT 12-AUG-2004 (first entry)
XX DE Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 149.
XX OS
XX KW apolipoprotein-E mimicking polypeptide; antilipemic; cardiant;
XX KW vasotropic; antiarteriosclerotic; cerebroprotective; antidiabetic;
XX KW serum cholesterol; coronary artery disease; dysbetalipoproteinemia;
XX KW atherosclerosis; myocardial infarction; stroke; embolus; angina;
XX KW low-density lipoprotein; LDL; very low density lipoprotein; VLDL.
XX OS Synthetic.
XX WO2004043403-A2.
XX PD 27-MAY-2004.
XX PF 13-NOV-2003; 2003WO-US036268.
XX PR 13-NOV-2002; 2002US-0425821P.
XX PA (UABR-) UAB RES FOUND.
XX PI Anantharamiah GM, Garber DW, Datta G;
XX PS WPI; 2004-411629/38.
XX DR

```

```

XX Synthetic apolipoprotein-E mimicking polypeptide useful for treating
PT coronary artery disease, dysbetalipoproteinemia or atherosclerosis
PT comprises an amino acid sequence.
XX
PS Claim 4; SEQ ID NO 149; 79pp; English.
XX
CC The invention relates to a novel synthetic apolipoprotein-E mimicking
CC polypeptide. The invention further comprises an isolated nucleic acid
CC encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector,
CC a host cell, a recombinant cell or a transgenic, non-human subject
CC (including animal or plant) comprising the synthetic apolipoprotein-E
CC mimicking polypeptide encoding polynucleotide; a composition comprising
CC the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and
CC an monoclonal antibody that specifically binds to the synthetic
CC apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E
CC mimicking polypeptide has the following activities: antilipemic, and
CC cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and
CC antianginal. The synthetic apolipoprotein-E mimicking polypeptide is
CC useful for reducing serum cholesterol in a subject (including a mammal
CC such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape,
CC chimpanzee or orangutan); for treating coronary artery disease,
CC dysbetalipoproteinemia or atherosclerosis; and for reducing the risk of
CC myocardial infarction or stroke; for breaking an embolus in the subject;
CC and also for treating angina. The synthetic apolipoprotein-E mimicking
CC polypeptide enhances binding of low-density lipoprotein (LDL) or very low
CC density lipoprotein (VLDL) to a cell and enhances degradation of LDL or
CC VLDL by a cell. This sequence represents a synthetic apolipoprotein-E
CC mimicking polypeptide of the invention.
XX
SQ Sequence 14 AA;

AD034372 Length: 14 February 14, 2007 16:01 Type: P Check: 8211 ..

1 GFRRIYGSIW RFRIR

!;AA SEQUENCE 1.0
ID_ADO34333 standard; peptide; 18 AA.
XX
AC ADO34333;
XX
DT 12-AUG-2004 (first entry)
XX
DE Synthetic apolipoprotein-E mimicking peptide, SEQ ID NO 110.
XX
KW apolipoprotein-E mimicking polypeptide; antilipemic; cardiant;
KW vasotropic; antiarteriosclerotic; cerebroprotective; antianginal;
KW serum cholesterol; coronary artery disease; dysbetalipoproteinemia;
KW atherosclerosis; myocardial infarction; stroke; embolus; angina;
KW low-density lipoprotein; LDL; very low density lipoprotein; VLDL.
XX
OS Synthetic.
XX
PN WO2004043403-A2.
XX
PD 27-MAY-2004.
XX
PF 13-NOV-2003; 2003WO-US036268.
XX
PR 13-NOV-2002; 2002US-0425821P.
XX
PA (UABR-) UAB RES FOUND.
XX
PI Anantharamiah GM, Garber DW, Datta G;
XX
DR WPI; 2004-411629/38.
XX
PT Synthetic apolipoprotein-E mimicking polypeptide useful for treating
PT coronary artery disease, dysbetalipoproteinemia or atherosclerosis
PT comprises an amino acid sequence.
XX
PS Claim 4; SEQ ID NO 110; 79pp; English.
XX

```

```

CC The invention relates to a novel synthetic apolipoprotein-E mimicking
CC polypeptide. The invention further comprises an isolated nucleic acid
CC encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector,
CC a host cell, a recombinant cell or a transgenic, non-human subject
CC (including animal or plant) comprising the synthetic apolipoprotein-E
CC mimicking polypeptide encoding polynucleotide; a composition comprising
CC the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and
CC an monoclonal antibody that specifically binds to the synthetic
CC apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E
CC mimicking polypeptide has the following activities: antilipemic, and
CC cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and
CC antianginal. The synthetic apolipoprotein-E mimicking polypeptide is
CC useful for reducing serum cholesterol in a subject (including a mammal
CC such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape,
CC chimpanzee or orangutan); for treating coronary artery disease,
CC dysbetalipoproteinemia or atherosclerosis; and for reducing the risk of
CC myocardial infarction or stroke; for breaking an embolus in the subject;
CC and also for treating angina. The synthetic apolipoprotein-E mimicking
CC polypeptide enhances binding of low-density lipoprotein (LDL) or very low
CC density lipoprotein (VLDL) to a cell and enhances degradation of LDL or
CC VLDL by a cell. This sequence represents a synthetic apolipoprotein-E
CC mimicking polypeptide of the invention.
XX
SQ Sequence 18 AA;

AD034333 Length: 18 February 14, 2007 16:01 Type: P Check: 3007 ..

1 GRRILGSFW RFFRIYIG

!;AA SEQUENCE 1.0
ID_ADO34333 standard; peptide; 18 AA.
XX
AC ADO34333;
XX
DT 12-AUG-2004 (first entry)
XX
DE Synthetic apolipoprotein-E mimicking peptide, SEQ ID NO 116.
XX
KW apolipoprotein-E mimicking polypeptide; antilipemic; cardiant;
KW vasotropic; antiarteriosclerotic; cerebroprotective; antianginal;
KW serum cholesterol; coronary artery disease; dysbetalipoproteinemia;
KW atherosclerosis; myocardial infarction; stroke; embolus; angina;
KW low-density lipoprotein; LDL; very low density lipoprotein; VLDL.
XX
OS Synthetic.
XX
PN WO2004043403-A2.
XX
PD 27-MAY-2004.
XX
PF 13-NOV-2003; 2003WO-US036268.
XX
PR 13-NOV-2002; 2002US-0425821P.
XX
PA (UABR-) UAB RES FOUND.
XX
PI Anantharamiah GM, Garber DW, Datta G;
XX
DR WPI; 2004-411629/38.
XX
PT Synthetic apolipoprotein-E mimicking polypeptide useful for treating
PT coronary artery disease, dysbetalipoproteinemia or atherosclerosis
PT comprises an amino acid sequence.
XX
PS Claim 4; SEQ ID NO 116; 79pp; English.
XX
CC The invention relates to a novel synthetic apolipoprotein-E mimicking
CC polypeptide. The invention further comprises an isolated nucleic acid
CC encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector,
CC a host cell, a recombinant cell or a transgenic, non-human subject
CC (including animal or plant) comprising the synthetic apolipoprotein-E
CC mimicking polypeptide encoding polynucleotide; a composition comprising
CC the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and
CC an monoclonal antibody that specifically binds to the synthetic
CC apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E
CC mimicking polypeptide has the following activities: antilipemic, and
CC cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and
CC antianginal. The synthetic apolipoprotein-E mimicking polypeptide is
CC useful for reducing serum cholesterol in a subject (including a mammal
CC such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape,
CC chimpanzee or orangutan); for treating coronary artery disease,
CC dysbetalipoproteinemia or atherosclerosis; and for reducing the risk of
CC myocardial infarction or stroke; for breaking an embolus in the subject;
CC and also for treating angina. The synthetic apolipoprotein-E mimicking
CC polypeptide enhances binding of low-density lipoprotein (LDL) or very low
CC density lipoprotein (VLDL) to a cell and enhances degradation of LDL or
CC VLDL by a cell. This sequence represents a synthetic apolipoprotein-E
CC mimicking polypeptide of the invention.
XX
SQ

```

an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E mimicking polypeptide has the following activities: antilipemic, and cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and antianginal. The synthetic apolipoprotein-E mimicking polypeptide is useful for reducing serum cholesterol in a subject (including a mammal such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape, chimpanzee or orangutan); for treating coronary artery disease, dysbetalipoproteinemia or atherosclerosis; and for reducing the risk of myocardial infarction or stroke; for breaking an embolus in the subject; and also for treating angina. The synthetic apolipoprotein-E mimicking polypeptide enhances binding of low-density lipoprotein (LDL) or very low density lipoprotein (VLDL) to a cell and enhances degradation of LDL or VLDL by a cell. This sequence represents a synthetic apolipoprotein-E mimicking polypeptide of the invention.

XX Sequence 18 AA;

AD034339 Length: 18 February 14, 2007 16:01 Type: P Check: 2998 ..

1 GRRFIGSIW RFIRAFYG

!!AA SEQUENCE 1.0
ID _AD034233 standard; peptide; 18 AA.

XX AC AD034233;

DT 12-AUG-2004 (first entry)

DE Synthetic apolipoprotein-E mimicking peptide, SEQ ID NO 10.

XX apolipoprotein-E mimicking polypeptide; antilipemic; cardiant;
KW vasotropic; antiarteriosclerotic; cerebroprotective; antianginal;
KW serum cholesterol; coronary artery disease; dysbetalipoproteinemia;
KW atherosclerosis; myocardial infarction; stroke; embolus; angina;
KW low-density lipoprotein; LDL; very low density lipoprotein; VLDL.

OS Synthetic.

XX WO2004043403-A2.

XX 27-MAY-2004.

XX 13-NOV-2003; 2003WO-US036268.

XX 13-NOV-2002; 2002US-0425821P.

XX (UABR-) UAB RES FOUND.

XX Anantharamiah GM, Garber DW, Datta G;

XX WPI; 2004-411629/38.

XX Synthetic apolipoprotein-E mimicking polypeptide useful for treating coronary artery disease, dysbetalipoproteinemia or atherosclerosis comprises an amino acid sequence.

XX Claim 4; SEQ ID NO 10; 79pp; English.

XX The invention relates to a novel synthetic apolipoprotein-E mimicking polypeptide. The invention further comprises an isolated nucleic acid encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector, a host cell, a recombinant cell or a transgenic, non-human subject (including animal or plant) comprising the synthetic apolipoprotein-E mimicking polypeptide encoding polynucleotide; a composition comprising the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E mimicking polypeptide has the following activities: antilipemic, cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and antianginal. The synthetic apolipoprotein-E mimicking polypeptide is useful for reducing serum cholesterol in a subject (including a mammal such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape,

CC chimpanzee or orangutan); for treating coronary artery disease, dysbetalipoproteinemia or atherosclerosis; and for reducing the risk of myocardial infarction or stroke; for breaking an embolus in the subject; and also for treating angina. The synthetic apolipoprotein-E mimicking polypeptide enhances binding of low-density lipoprotein (LDL) or very low density lipoprotein (VLDL) to a cell and enhances degradation of LDL or VLDL by a cell. This sequence represents a synthetic apolipoprotein-E mimicking polypeptide of the invention.

XX Sequence 18 AA;

AD034233 Length: 18 February 14, 2007 16:01 Type: P Check: 3010 ..

1 GIRFLGSIW RFIRAFYG

!!AA SEQUENCE 1.0

ID _AD034335 standard; peptide; 18 AA.

XX AC AD034335;

DT 12-AUG-2004 (first entry)

DE Synthetic apolipoprotein-E mimicking peptide, SEQ ID NO 112.

XX apolipoprotein-E mimicking polypeptide; antilipemic; cardiant;
KW vasotropic; antiarteriosclerotic; cerebroprotective; antianginal;
KW serum cholesterol; coronary artery disease; dysbetalipoproteinemia;
KW atherosclerosis; myocardial infarction; stroke; embolus; angina;
KW low-density lipoprotein; LDL; very low density lipoprotein; VLDL.

OS Synthetic.

XX WO2004043403-A2.

XX 27-MAY-2004.

XX 13-NOV-2003; 2003WO-US036268.

XX 13-NOV-2002; 2002US-0425821P.

XX (UABR-) UAB RES FOUND.

XX Anantharamiah GM, Garber DW, Datta G;

XX WPI; 2004-411629/38.

XX Synthetic apolipoprotein-E mimicking polypeptide useful for treating coronary artery disease, dysbetalipoproteinemia or atherosclerosis comprises an amino acid sequence.

XX Claim 4; SEQ ID NO 112; 79pp; English.

XX The invention relates to a novel synthetic apolipoprotein-E mimicking polypeptide. The invention further comprises an isolated nucleic acid encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector, a host cell, a recombinant cell or a transgenic, non-human subject (including animal or plant) comprising the synthetic apolipoprotein-E mimicking polypeptide encoding polynucleotide; a composition comprising the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and an monoclonal antibody that specifically binds to the synthetic apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E mimicking polypeptide has the following activities: antilipemic, cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and antianginal. The synthetic apolipoprotein-E mimicking polypeptide is useful for reducing serum cholesterol in a subject (including a mammal such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape, chimpanzee or orangutan); for treating coronary artery disease, dysbetalipoproteinemia or atherosclerosis; and for reducing the risk of myocardial infarction or stroke; for breaking an embolus in the subject; and also for treating angina. The synthetic apolipoprotein-E mimicking polypeptide enhances binding of low-density lipoprotein (LDL) or very low density lipoprotein (VLDL) to a cell and enhances degradation of LDL or VLDL by a cell. This sequence represents a synthetic apolipoprotein-E

```

CC mimicking polypeptide of the invention.
XX
SQ Sequence 18 AA;
ADO34335 Length: 18 February 14, 2007 16:01 Type: P Check: 3019
1 GFRILGSIW RFIRAFYG
!!AA_SEQUENCE 1.0
ID_ADO34234 standard; peptide; 14 AA.
XX
AC ADO34234;
XX
DT 12-AUG-2004 (first entry)
XX
DE Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 11.
XX
KW apolipoprotein-E mimicking polypeptide; antilipaeamic; cardiant;
KW vasotropic; antiarteriosclerotic; cerebroprotective; antiangiinal;
KW serum cholesterol; coronary artery disease; dysbetalipoproteinaemia;
KW atherosclerosis; myocardial infarction; stroke; embolus; angina;
KW low-density lipoprotein; LDL; very low density lipoprotein; VLDL.
XX
OS Synthetic.
XX
PN WO2004043403-A2.
XX
PD 27-MAY-2004.
XX
PF 13-NOV-2003; 2003WO-US036268.
XX
PR 13-NOV-2002; 2002US-0425821P.
XX
PA (UABR-) UAB RES FOUND.
XX
PI Anantharamiah GM, Garber DW, Datta G;
XX WPI; 2004-411629/38.
XX
PT Synthetic apolipoprotein-E mimicking polypeptide useful for treating
PT coronary artery disease, dysbetalipoproteinemia or atherosclerosis
PT comprises an amino acid sequence.
XX
PS Claim 4; SEQ ID NO 11; 79pp; English.
XX
CC The invention relates to a novel synthetic apolipoprotein-E mimicking
CC polypeptide. The invention further comprises an isolated nucleic acid
CC encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector,
CC a host cell, a recombinant cell or a transgenic, non-human subject
CC (including animal or plant) comprising the synthetic apolipoprotein-E
CC mimicking polypeptide encoding polynucleotide; a composition comprising
CC the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and
CC an monoclonal antibody that specifically binds to the synthetic
CC apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E
CC mimicking polypeptide has the following activities: antilipaeamic,
CC cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and
CC antiangiinal. The synthetic apolipoprotein-E mimicking polypeptide is
CC useful for reducing serum cholesterol in a subject (including a mammal
CC such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape,
CC chimpanzee or orangutan); for treating coronary artery disease,
CC dysbetalipoproteinaemia or atherosclerosis; and for reducing the risk of
CC myocardial infarction or stroke; for breaking an embolus in the subject;
CC and also for treating angina. The synthetic apolipoprotein-E mimicking
CC polypeptide enhances binding of low-density lipoprotein (LDL) or very low
CC density lipoprotein (VLDL) to a cell and enhances degradation of LDL or
CC VLDL by a cell. This sequence represents a synthetic apolipoprotein-E
CC mimicking polypeptide of the invention.
XX
SQ Sequence 14 AA;
ADO34234 Length: 14 February 14, 2007 16:01 Type: P Check: 8202
1 GIRRFYGSIW RFIR
!!AA_SEQUENCE 1.0
ID_ADO34234 standard; peptide; 14 AA.
XX
AC ADO34417;
XX
DT 12-AUG-2004 (first entry)
XX
DE Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 21.
XX
KW apolipoprotein-E mimicking polypeptide; antilipaeamic; cardiant;
KW vasotropic; antiarteriosclerotic; cerebroprotective; antiangiinal;
KW serum cholesterol; coronary artery disease; dysbetalipoproteinaemia;
KW atherosclerosis; myocardial infarction; stroke; embolus; angina;
KW low-density lipoprotein; LDL; very low density lipoprotein; VLDL.
XX
OS Synthetic.
XX
PN WO2004043403-A2.
XX
PD 27-MAY-2004.
XX
PF 13-NOV-2003; 2003WO-US036268.
XX
PR 13-NOV-2002; 2002US-0425821P.
XX
PA (UABR-) UAB RES FOUND.
XX
PI Anantharamiah GM, Garber DW, Datta G;
XX WPI; 2004-411629/38.
XX
PT Synthetic apolipoprotein-E mimicking polypeptide useful for treating
PT coronary artery disease, dysbetalipoproteinemia or atherosclerosis
PT comprises an amino acid sequence.
XX
PS Claim 4; SEQ ID NO 21; 79pp; English.
XX
CC The invention relates to a novel synthetic apolipoprotein-E mimicking
CC polypeptide. The invention further comprises an isolated nucleic acid
CC encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector,
CC a host cell, a recombinant cell or a transgenic, non-human subject
CC (including animal or plant) comprising the synthetic apolipoprotein-E
CC mimicking polypeptide encoding polynucleotide; a composition comprising
CC the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and
CC an monoclonal antibody that specifically binds to the synthetic
CC apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E
CC mimicking polypeptide has the following activities: antilipaeamic,
CC cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and
CC antiangiinal. The synthetic apolipoprotein-E mimicking polypeptide is
CC useful for reducing serum cholesterol in a subject (including a mammal
CC such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape,
CC chimpanzee or orangutan); for treating coronary artery disease,
CC dysbetalipoproteinaemia or atherosclerosis; and for reducing the risk of
CC myocardial infarction or stroke; for breaking an embolus in the subject;
CC and also for treating angina. The synthetic apolipoprotein-E mimicking
CC polypeptide enhances binding of low-density lipoprotein (LDL) or very low
CC density lipoprotein (VLDL) to a cell and enhances degradation of LDL or
CC VLDL by a cell. This sequence represents a synthetic apolipoprotein-E
CC mimicking polypeptide of the invention.
XX
SQ Sequence 18 AA;
ADO34244 Length: 18 February 14, 2007 16:01 Type: P Check: 3136
1 GIRRFLGAIW RFIRSFYG
!!AA_SEQUENCE 1.0
ID_ADO34417 standard; peptide; 14 AA.
XX
AC ADO34417;
XX
DT 12-AUG-2004 (first entry)
XX
DE Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 21.
XX
KW apolipoprotein-E mimicking polypeptide; antilipaeamic; cardiant;
KW vasotropic; antiarteriosclerotic; cerebroprotective; antiangiinal;
KW serum cholesterol; coronary artery disease; dysbetalipoproteinaemia;
KW atherosclerosis; myocardial infarction; stroke; embolus; angina;
KW low-density lipoprotein; LDL; very low density lipoprotein; VLDL.
XX
OS Synthetic.
XX
PN WO2004043403-A2.
XX
PD 27-MAY-2004.
XX
PF 13-NOV-2003; 2003WO-US036268.
XX
PR 13-NOV-2002; 2002US-0425821P.
XX
PA (UABR-) UAB RES FOUND.
XX
PI Anantharamiah GM, Garber DW, Datta G;
XX WPI; 2004-411629/38.
XX
PT Synthetic apolipoprotein-E mimicking polypeptide useful for treating
PT coronary artery disease, dysbetalipoproteinemia or atherosclerosis
PT comprises an amino acid sequence.
XX
PS Claim 4; SEQ ID NO 21; 79pp; English.
XX
CC The invention relates to a novel synthetic apolipoprotein-E mimicking
CC polypeptide. The invention further comprises an isolated nucleic acid
CC encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector,
CC a host cell, a recombinant cell or a transgenic, non-human subject
CC (including animal or plant) comprising the synthetic apolipoprotein-E
CC mimicking polypeptide encoding polynucleotide; a composition comprising
CC the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and
CC an monoclonal antibody that specifically binds to the synthetic
CC apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E
CC mimicking polypeptide has the following activities: antilipaeamic,
CC cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and
CC antiangiinal. The synthetic apolipoprotein-E mimicking polypeptide is
CC useful for reducing serum cholesterol in a subject (including a mammal
CC such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape,
CC chimpanzee or orangutan); for treating coronary artery disease,
CC dysbetalipoproteinaemia or atherosclerosis; and for reducing the risk of
CC myocardial infarction or stroke; for breaking an embolus in the subject;
CC and also for treating angina. The synthetic apolipoprotein-E mimicking
CC polypeptide enhances binding of low-density lipoprotein (LDL) or very low
CC density lipoprotein (VLDL) to a cell and enhances degradation of LDL or
CC VLDL by a cell. This sequence represents a synthetic apolipoprotein-E
CC mimicking polypeptide of the invention.
XX
SQ Sequence 18 AA;

```

```

XX DE Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 194.
XX
XX KW apolipoprotein-E mimicking polypeptide; antilipaeamic; cardiant;
XX KW vasotropic; antiarteriosclerotic; cerebroprotective; antianginal;
XX KW serum cholesterol; coronary artery disease; dysbetalipoproteinaemia;
XX KW atherosclerosis; myocardial infarction; stroke; embolus; angina;
XX KW low-density lipoprotein; LDL; very low density lipoprotein; VLDL.
XX OS Synthetic.
XX
XX PN WO2004043403-A2.
XX PD 27-MAY-2004.
XX
XX PF 13-NOV-2003; 2003WO-US036268.
XX
XX PR 13-NOV-2002; 2002US-0425821P.
XX
XX PA (UABR-) UAB RES FOUND.
XX
XX PI Anantharamiah GM, Garber DW, Datta G;
XX
XX DR WPI; 2004-411629/38.
XX
XX KW Synthetic apolipoprotein-E mimicking polypeptide useful for treating
XX PT coronary artery disease, dysbetalipoproteinaemia or atherosclerosis
XX PT comprises an amino acid sequence.
XX
XX PS Claim 4; SEQ ID NO 194; 79pp; English.
XX
XX CC The invention relates to a novel synthetic apolipoprotein-E mimicking
XX CC polypeptide. The invention further comprises an isolated nucleic acid
XX CC encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector,
XX CC a host cell, a recombinant cell or a transgenic, non-human subject
XX CC (including animal or plant) comprising the synthetic apolipoprotein-E
XX CC mimicking polypeptide encoding polynucleotide; a composition comprising
XX CC the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and
XX CC an monoclonal antibody that specifically binds to the synthetic
XX CC apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E
XX CC mimicking polypeptide has the following activities: antilipaeamic,
XX CC cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and
XX CC antianginal. The synthetic apolipoprotein-E mimicking polypeptide is
XX CC useful for reducing serum cholesterol in a subject (including a mammal
XX CC such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape,
XX CC chimpanzee or orangutan); for treating coronary artery disease,
XX CC dysbetalipoproteinaemia or atherosclerosis; and for reducing the risk of
XX CC myocardial infarction or stroke; for breaking an embolus in the subject;
XX CC and also for treating angina. The synthetic apolipoprotein-E mimicking
XX CC polypeptide enhances binding of low-density lipoprotein (LDL) or very low
XX CC density lipoprotein (VLDL) to a cell and enhances degradation of LDL or
XX CC VLDL by a cell. This sequence represents a synthetic apolipoprotein-E
XX CC mimicking polypeptide of the invention.
XX
XX SQ Sequence 14 AA;
AD034417 Length: 14 February 14, 2007 16:01 Type: P Check: 8210 ..
1 GIRRYFGSLW RFIR
!!AA_SEQUENCE 1.0
ID_ADO34337 standard; peptide; 18 AA.
XX
XX AC ADO34337;
XX
XX DT 12-AUG-2004 (first entry)
XX
XX DE Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 114.
XX
XX KW apolipoprotein-E mimicking polypeptide; antilipaeamic; cardiant;
XX KW vasotropic; antiarteriosclerotic; cerebroprotective; antianginal;
XX KW serum cholesterol; coronary artery disease; dysbetalipoproteinaemia;
XX KW atherosclerosis; myocardial infarction; stroke; embolus; angina;

```

```

KW low-density lipoprotein; LDL; very low density lipoprotein; VLDL.
XX
XX OS Synthetic.
XX
XX PN WO2004043403-A2.
XX PD 27-MAY-2004.
XX
XX PF 13-NOV-2003; 2003WO-US036268.
XX
XX PR 13-NOV-2002; 2002US-0425821P.
XX
XX PA (UABR-) UAB RES FOUND.
XX
XX PI Anantharamiah GM, Garber DW, Datta G;
XX
XX DR WPI; 2004-411629/38.
XX
XX KW Synthetic apolipoprotein-E mimicking polypeptide useful for treating
XX PT coronary artery disease, dysbetalipoproteinaemia or atherosclerosis
XX PT comprises an amino acid sequence.
XX
XX PS Claim 4; SEQ ID NO 114; 79pp; English.
XX
XX CC The invention relates to a novel synthetic apolipoprotein-E mimicking
XX CC polypeptide. The invention further comprises an isolated nucleic acid
XX CC encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector,
XX CC a host cell, a recombinant cell or a transgenic, non-human subject
XX CC (including animal or plant) comprising the synthetic apolipoprotein-E
XX CC mimicking polypeptide encoding polynucleotide; a composition comprising
XX CC the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and
XX CC an monoclonal antibody that specifically binds to the synthetic
XX CC apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E
XX CC mimicking polypeptide has the following activities: antilipaeamic,
XX CC cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and
XX CC antianginal. The synthetic apolipoprotein-E mimicking polypeptide is
XX CC useful for reducing serum cholesterol in a subject (including a mammal
XX CC such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape,
XX CC chimpanzee or orangutan); for treating coronary artery disease,
XX CC dysbetalipoproteinaemia or atherosclerosis; and for reducing the risk of
XX CC myocardial infarction or stroke; for breaking an embolus in the subject;
XX CC and also for treating angina. The synthetic apolipoprotein-E mimicking
XX CC polypeptide enhances binding of low-density lipoprotein (LDL) or very low
XX CC density lipoprotein (VLDL) to a cell and enhances degradation of LDL or
XX CC VLDL by a cell. This sequence represents a synthetic apolipoprotein-E
XX CC mimicking polypeptide of the invention.
XX
XX SQ Sequence 18 AA;
AD034337 Length: 18 February 14, 2007 16:01 Type: P Check: 3019 ..
1 GIRRFLGSFW RIIRAFYG
!!AA_SEQUENCE 1.0
ID_ADO34343 standard; peptide; 18 AA.
XX
XX AC ADO34343;
XX
XX DT 12-AUG-2004 (first entry)
XX
XX DE Synthetic apolipoprotein-E mimicking peptide, SEQ ID No 120.
XX
XX KW apolipoprotein-E mimicking polypeptide; antilipaeamic; cardiant;
XX KW vasotropic; antiarteriosclerotic; cerebroprotective; antianginal;
XX KW serum cholesterol; coronary artery disease; dysbetalipoproteinaemia;
XX KW atherosclerosis; myocardial infarction; stroke; embolus; angina;
XX KW low-density lipoprotein; LDL; very low density lipoprotein; VLDL.
XX
XX OS Synthetic.
XX
XX PN WO2004043403-A2.
XX PD 27-MAY-2004.

```

```

XX PF 13-NOV-2003; 2003WO-US036268.
XX PR 13-NOV-2002; 2002US-0425821P.
XX PA (UABR-) UAB RES FOUND.
XX PI Anantharamiah GM, Garber DW, Datta G;
XX DR WPI; 2004-411629/38.
XX XX
XX XX Synthetic apolipoprotein-E mimicking polypeptide useful for treating
XX PT coronary artery disease, dysbetalipoproteinemia or atherosclerosis
XX PT comprises an amino acid sequence.
XX XX
XX PS Claim 4; SEQ ID NO 120; 79pp; English.
XX XX
XX CC The invention relates to a novel synthetic apolipoprotein-E mimicking
XX CC polypeptide. The invention further comprises an isolated nucleic acid
XX CC encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector,
XX CC a host cell, a recombinant cell or a transgenic, non-human subject
XX CC (including animal or plant) comprising the synthetic apolipoprotein-E
XX CC mimicking polypeptide encoding polynucleotide; a composition comprising
XX CC the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and
XX CC an monoclonal antibody that specifically binds to the synthetic
XX CC apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E
XX CC mimicking polypeptide has the following activities: antilipemic,
XX CC cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and
XX CC antidiabetic. The synthetic apolipoprotein-E mimicking polypeptide is
XX CC useful for reducing serum cholesterol in a subject (including a mammal
XX CC such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape,
XX CC chimpanzee or orangutan); for treating coronary artery disease,
XX CC dysbetalipoproteinemia or atherosclerosis; and for reducing the risk of
XX CC myocardial infarction or stroke; for breaking an embolus in the subject;
XX CC and also for treating angina. The synthetic apolipoprotein-E mimicking
XX CC polypeptide enhances binding of low-density lipoprotein (LDL) or very low
XX CC density lipoprotein (VLDL) to a cell and enhances degradation of LDL or
XX CC VLDL by a cell. This sequence represents a synthetic apolipoprotein-E
XX CC mimicking polypeptide of the invention.
XX XX
XX SQ Sequence 18 AA;
XX XX
AD034343 Length: 18 February 14, 2007 16:01 Type: P Check: 2996 ..
1 GRRFLGSIY RPIAFWG
!!AA SEQUENCE 1.0
ID ADO34342 standard; peptide; 18 AA.
XX AC ADO34342;
XX XX
XX DT 12-AUG-2004 (first entry)
XX XX
XX DE Synthetic apolipoprotein-E mimicking peptide, SEQ ID NO 119.
XX XX
XX KW apolipoprotein-E mimicking polypeptide; antilipemic; cardiant;
XX KW vasotropic; antiarteriosclerotic; cerebroprotective; antidiabetic;
XX KW serum cholesterol; coronary artery disease; dysbetalipoproteinemia;
XX KW atherosclerosis; myocardial infarction; stroke; embolus; angina;
XX KW low-density lipoprotein; LDL; very low density lipoprotein; VLDL.
XX OS Synthetic.
XX XX
XX PN WO2004043403-A2.
XX XX
XX PD 27-MAY-2004.
XX XX
XX PF 13-NOV-2003; 2003WO-US036268.
XX XX
XX PR 13-NOV-2002; 2002US-0425821P.
XX XX
XX PA (UABR-) UAB RES FOUND.
XX XX
XX PI Anantharamiah GM, Garber DW, Datta G;
XX DR WPI; 2004-411629/38.
XX XX
XX XX Synthetic apolipoprotein-E mimicking polypeptide useful for treating
XX PT coronary artery disease, dysbetalipoproteinemia or atherosclerosis
XX PT comprises an amino acid sequence.
XX XX
XX XX

```

```

PI Anantharamiah GM, Garber DW, Datta G;
XX WPI; 2004-411629/38.
XX XX
XX XX Synthetic apolipoprotein-E mimicking polypeptide useful for treating
XX PT coronary artery disease, dysbetalipoproteinemia or atherosclerosis
XX PT comprises an amino acid sequence.
XX XX
XX PS Claim 4; SEQ ID NO 119; 79pp; English.
XX XX
XX CC The invention relates to a novel synthetic apolipoprotein-E mimicking
XX CC polypeptide. The invention further comprises an isolated nucleic acid
XX CC encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector,
XX CC a host cell, a recombinant cell or a transgenic, non-human subject
XX CC (including animal or plant) comprising the synthetic apolipoprotein-E
XX CC mimicking polypeptide encoding polynucleotide; a composition comprising
XX CC the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and
XX CC an monoclonal antibody that specifically binds to the synthetic
XX CC apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E
XX CC mimicking polypeptide has the following activities: antilipemic,
XX CC cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and
XX CC antidiabetic. The synthetic apolipoprotein-E mimicking polypeptide is
XX CC useful for reducing serum cholesterol in a subject (including a mammal
XX CC such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape,
XX CC chimpanzee or orangutan); for treating coronary artery disease,
XX CC dysbetalipoproteinemia or atherosclerosis; and for reducing the risk of
XX CC myocardial infarction or stroke; for breaking an embolus in the subject;
XX CC and also for treating angina. The synthetic apolipoprotein-E mimicking
XX CC polypeptide enhances binding of low-density lipoprotein (LDL) or very low
XX CC density lipoprotein (VLDL) to a cell and enhances degradation of LDL or
XX CC VLDL by a cell. This sequence represents a synthetic apolipoprotein-E
XX CC mimicking polypeptide of the invention.
XX XX
XX SQ Sequence 18 AA;
XX XX
AD034342 Length: 18 February 14, 2007 16:01 Type: P Check: 3061 ..
1 GRRFLGSFW RIIRAIYG
!!AA SEQUENCE 1.0
ID ADO34360 standard; peptide; 14 AA.
XX AC ADO34360;
XX XX
XX DT 12-AUG-2004 (first entry)
XX XX
XX DE Synthetic apolipoprotein-E mimicking peptide, SEQ ID NO 137.
XX XX
XX KW apolipoprotein-E mimicking polypeptide; antilipemic; cardiant;
XX KW vasotropic; antiarteriosclerotic; cerebroprotective; antidiabetic;
XX KW serum cholesterol; coronary artery disease; dysbetalipoproteinemia;
XX KW atherosclerosis; myocardial infarction; stroke; embolus; angina;
XX KW low-density lipoprotein; LDL; very low density lipoprotein; VLDL.
XX OS Synthetic.
XX XX
XX PN WO2004043403-A2.
XX XX
XX PD 27-MAY-2004.
XX XX
XX PF 13-NOV-2003; 2003WO-US036268.
XX XX
XX PR 13-NOV-2002; 2002US-0425821P.
XX XX
XX PA (UABR-) UAB RES FOUND.
XX XX
XX PI Anantharamiah GM, Garber DW, Datta G;
XX DR WPI; 2004-411629/38.
XX XX
XX XX Synthetic apolipoprotein-E mimicking polypeptide useful for treating
XX PT coronary artery disease, dysbetalipoproteinemia or atherosclerosis
XX PT comprises an amino acid sequence.
XX XX

```

```

XX PS Claim 4; SEQ ID NO 137; 79pp; English.
XX CC The invention relates to a novel synthetic apolipoprotein-E mimicking
XX CC polypeptide. The invention further comprises an isolated nucleic acid
XX CC encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector,
XX CC a host cell, a recombinant cell or a transgenic, non-human subject
XX CC (including animal or plant) comprising the synthetic apolipoprotein-E
XX CC mimicking polypeptide encoding polynucleotide; a composition comprising
XX CC the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and
XX CC an monoclonal antibody that specifically binds to the synthetic
XX CC apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E
XX CC mimicking polypeptide has the following activities: antilipemic,
XX CC cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and
XX CC antianginal. The synthetic apolipoprotein-E mimicking polypeptide is
XX CC useful for reducing serum cholesterol in a subject (including a mammal
XX CC such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape,
XX CC chimpanzee or orangutan); for treating coronary artery disease,
XX CC dysbetalipoproteinemia or atherosclerosis; and for reducing the risk of
XX CC myocardial infarction or stroke; for breaking an embolus in the subject;
XX CC and also for treating angina. The synthetic apolipoprotein-E mimicking
XX CC polypeptide enhances binding of low-density lipoprotein (LDL) or very low
XX CC density lipoprotein (VLDL) to a cell and enhances degradation of LDL or
XX CC VLDL by a cell. This sequence represents a synthetic apolipoprotein-E
XX CC mimicking polypeptide of the invention.
XX SQ Sequence 14 AA;
AD034360 Length: 14 February 14, 2007 16:01 Type: P Check: 8274
1 GLRRYGLSLW RFLR
!!AA SEQUENCE 1.0
ID _AD034426 standard; peptide; 14 AA.
XX AC AD034426;
XX KW apolipoprotein-E mimicking polypeptide; antilipemic; cardiant;
XX KW vasotropic; antiarteriosclerotic; cerebroprotective; antianginal;
XX KW serum cholesterol; coronary artery disease; dysbetalipoproteinemia;
XX KW atherosclerosis; myocardial infarction; stroke; embolus; angina;
XX KW low-density lipoprotein; LDL; very low density lipoprotein; VLDL.
XX OS Synthetic.
XX PN WO2004043403-A2.
XX PD 27-MAY-2004.
XX DT 12-AUG-2004 (first entry)
XX DE Synthetic apolipoprotein-E mimicking peptide, SEQ ID NO 203.
XX KW apolipoprotein-E mimicking polypeptide; antilipemic; cardiant;
XX KW vasotropic; antiarteriosclerotic; cerebroprotective; antianginal;
XX KW serum cholesterol; coronary artery disease; dysbetalipoproteinemia;
XX KW atherosclerosis; myocardial infarction; stroke; embolus; angina;
XX KW low-density lipoprotein; LDL; very low density lipoprotein; VLDL.
XX OS Synthetic.
XX PN WO2004043403-A2.
XX PD 27-MAY-2004.
XX DT 13-NOV-2003; 2003WO-US036268.
XX PR 13-NOV-2002; 2002US-0425821P.
XX PA (UABR-) UAB RES FOUND.
XX PI Anantharamiah GM, Garber DW, Datta G;
XX DR WPI; 2004-411629/38.
XX CC Synthetic apolipoprotein-E mimicking polypeptide useful for treating
XX CC coronary artery disease, dysbetalipoproteinemia or atherosclerosis
XX CC comprises an amino acid sequence.
XX PS Claim 4; SEQ ID NO 203; 79pp; English.
XX CC The invention relates to a novel synthetic apolipoprotein-E mimicking
XX CC polypeptide. The invention further comprises an isolated nucleic acid
XX CC encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector,
XX CC a host cell, a recombinant cell or a transgenic, non-human subject

```

```

XX CC (including animal or plant) comprising the synthetic apolipoprotein-E
XX CC mimicking polypeptide encoding polynucleotide; a composition comprising
XX CC the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and
XX CC an monoclonal antibody that specifically binds to the synthetic
XX CC apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E
XX CC mimicking polypeptide has the following activities: antilipemic,
XX CC cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and
XX CC antianginal. The synthetic apolipoprotein-E mimicking polypeptide is
XX CC useful for reducing serum cholesterol in a subject (including a mammal
XX CC such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape,
XX CC chimpanzee or orangutan); for treating coronary artery disease,
XX CC dysbetalipoproteinemia or atherosclerosis; and for reducing the risk of
XX CC myocardial infarction or stroke; for breaking an embolus in the subject;
XX CC and also for treating angina. The synthetic apolipoprotein-E mimicking
XX CC polypeptide enhances binding of low-density lipoprotein (LDL) or very low
XX CC density lipoprotein (VLDL) to a cell and enhances degradation of LDL or
XX CC VLDL by a cell. This sequence represents a synthetic apolipoprotein-E
XX CC mimicking polypeptide of the invention.
XX SQ Sequence 14 AA;
AD034426 Length: 14 February 14, 2007 16:01 Type: P Check: 8214
1 GFRRLYSGIW RPIR
!!AA SEQUENCE 1.0
ID _AD034241 standard; peptide; 18 AA.
XX AC AD034241;
XX DT 12-AUG-2004 (first entry)
XX DE Synthetic apolipoprotein-E mimicking peptide, SEQ ID NO 18.
XX KW apolipoprotein-E mimicking polypeptide; antilipemic; cardiant;
XX KW vasotropic; antiarteriosclerotic; cerebroprotective; antianginal;
XX KW serum cholesterol; coronary artery disease; dysbetalipoproteinemia;
XX KW atherosclerosis; myocardial infarction; stroke; embolus; angina;
XX KW low-density lipoprotein; LDL; very low density lipoprotein; VLDL.
XX OS Synthetic.
XX PN WO2004043403-A2.
XX PD 27-MAY-2004.
XX DT 13-NOV-2003; 2003WO-US036268.
XX PR 13-NOV-2002; 2002US-0425821P.
XX PA (UABR-) UAB RES FOUND.
XX PI Anantharamiah GM, Garber DW, Datta G;
XX DR WPI; 2004-411629/38.
XX CC Synthetic apolipoprotein-E mimicking polypeptide useful for treating
XX CC coronary artery disease, dysbetalipoproteinemia or atherosclerosis
XX CC comprises an amino acid sequence.
XX PS Claim 4; SEQ ID NO 18; 79pp; English.
XX CC The invention relates to a novel synthetic apolipoprotein-E mimicking
XX CC polypeptide. The invention further comprises an isolated nucleic acid
XX CC encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector,
XX CC a host cell, a recombinant cell or a transgenic, non-human subject
XX CC (including animal or plant) comprising the synthetic apolipoprotein-E
XX CC mimicking polypeptide encoding polynucleotide; a composition comprising
XX CC the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and
XX CC an monoclonal antibody that specifically binds to the synthetic
XX CC apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E
XX CC mimicking polypeptide has the following activities: antilipemic,
XX CC cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and

```

CC antianginal. The synthetic apolipoprotein-E mimicking polypeptide is
 CC useful for reducing serum cholesterol in a subject (including a mammal
 CC such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape,
 CC chimpanzee or orangutan); for treating coronary artery disease,
 CC dysbetalipoproteinemia or atherosclerosis; and for reducing the risk of
 CC myocardial infarction or stroke; for breaking an embolus in the subject;
 CC and also for treating angina. The synthetic apolipoprotein-E mimicking
 CC polypeptide enhances binding of low-density lipoprotein (LDL) or very low
 CC density lipoprotein (VLDL) to a cell and enhances degradation of LDL or
 CC VLDL by a cell. This sequence represents a synthetic apolipoprotein-E
 CC mimicking polypeptide of the invention.

XX Sequence 18 AA;

AD034241 Length: 18 February 14, 2007 16:01 Type: P Check: 2998

1 GIRFLSGIW RFIRAFYG

!!AA SEQUENCE 1.0

ID -AD034418 standard; peptide; 14 AA.

XX AC AD034418;

DT 12-AUG-2004 (first entry)

XX Synthetic apolipoprotein-E mimicking peptide, SEQ ID NO 195.

XX apolipoprotein-E mimicking polypeptide; antilipaeamic; cardiant;
 KW vasotropic; antiarteriosclerotic; cerebroprotective; antianginal;
 KW serum cholesterol; coronary artery disease; dysbetalipoproteinemia;
 KW atherosclerosis; myocardial infarction; stroke; embolus; angina;
 KW low-density lipoprotein; LDL; very low density lipoprotein; VLDL.

XX Synthetic.

XX WO2004043403-A2.

XX 27-MAY-2004.

PF 13-NOV-2003; 2003WO-US036268.

PR 13-NOV-2002; 2002US-0425821P.

XX (UABR-) UAB RES FOUND.

PI Anantharamiah GM, Garber DW, Datta G;

XX WPI; 2004-411629/38.

XX Synthetic apolipoprotein-E mimicking polypeptide useful for treating
 CC coronary artery disease, dysbetalipoproteinemia or atherosclerosis
 CC comprises an amino acid sequence.

XX Claim 4; SEQ ID NO 195; 79pp; English.

XX The invention relates to a novel synthetic apolipoprotein-E mimicking
 CC polypeptide. The invention further comprises an isolated nucleic acid
 CC encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector,
 CC a host cell, a recombinant cell or a transgenic, non-human subject
 CC (including animal or plant) comprising the synthetic apolipoprotein-E
 CC mimicking polypeptide encoding polynucleotide; a composition comprising
 CC the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and
 CC an monoclonal antibody that specifically binds to the synthetic
 CC apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E
 CC mimicking polypeptide has the following activities: antilipaeamic,
 CC cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and
 CC antianginal. The synthetic apolipoprotein-E mimicking polypeptide is
 CC useful for reducing serum cholesterol in a subject (including a mammal
 CC such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape,
 CC chimpanzee or orangutan); for treating coronary artery disease,
 CC dysbetalipoproteinemia or atherosclerosis; and for reducing the risk of
 CC myocardial infarction or stroke; for breaking an embolus in the subject;
 CC and also for treating angina. The synthetic apolipoprotein-E mimicking

CC polypeptide enhances binding of low-density lipoprotein (LDL) or very low
 CC density lipoprotein (VLDL) to a cell and enhances degradation of LDL or
 CC VLDL by a cell. This sequence represents a synthetic apolipoprotein-E
 CC mimicking polypeptide of the invention.

XX Sequence 14 AA;

AD034418 Length: 14 February 14, 2007 16:01 Type: P Check: 8228

1 GLRRYFGSIW RFLR

!!AA SEQUENCE 1.0

ID -AD034350 standard; peptide; 18 AA.

XX AC AD034350;

DT 12-AUG-2004 (first entry)

XX Synthetic apolipoprotein-E mimicking peptide, SEQ ID NO 127.

XX apolipoprotein-E mimicking polypeptide; antilipaeamic; cardiant;
 KW vasotropic; antiarteriosclerotic; cerebroprotective; antianginal;
 KW serum cholesterol; coronary artery disease; dysbetalipoproteinemia;
 KW atherosclerosis; myocardial infarction; stroke; embolus; angina;
 KW low-density lipoprotein; LDL; very low density lipoprotein; VLDL.

XX Synthetic.

XX WO2004043403-A2.

XX 27-MAY-2004.

PF 13-NOV-2003; 2003WO-US036268.

PR 13-NOV-2002; 2002US-0425821P.

XX (UABR-) UAB RES FOUND.

PI Anantharamiah GM, Garber DW, Datta G;

XX WPI; 2004-411629/38.

XX Synthetic apolipoprotein-E mimicking polypeptide useful for treating
 CC coronary artery disease, dysbetalipoproteinemia or atherosclerosis
 CC comprises an amino acid sequence.

XX Claim 4; SEQ ID NO 127; 79pp; English.

XX The invention relates to a novel synthetic apolipoprotein-E mimicking
 CC polypeptide. The invention further comprises an isolated nucleic acid
 CC encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector,
 CC a host cell, a recombinant cell or a transgenic, non-human subject
 CC (including animal or plant) comprising the synthetic apolipoprotein-E
 CC mimicking polypeptide encoding polynucleotide; a composition comprising
 CC the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and
 CC an monoclonal antibody that specifically binds to the synthetic
 CC apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E
 CC mimicking polypeptide has the following activities: antilipaeamic,
 CC cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and
 CC antianginal. The synthetic apolipoprotein-E mimicking polypeptide is
 CC useful for reducing serum cholesterol in a subject (including a mammal
 CC such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape,
 CC chimpanzee or orangutan); for treating coronary artery disease,
 CC dysbetalipoproteinemia or atherosclerosis; and for reducing the risk of
 CC myocardial infarction or stroke; for breaking an embolus in the subject;
 CC and also for treating angina. The synthetic apolipoprotein-E mimicking
 CC polypeptide enhances binding of low-density lipoprotein (LDL) or very low
 CC density lipoprotein (VLDL) to a cell and enhances degradation of LDL or
 CC VLDL by a cell. This sequence represents a synthetic apolipoprotein-E
 CC mimicking polypeptide of the invention.

XX Sequence 18 AA;

AD034350 Length: 18 February 14, 2007 16:01 Type: P Check: 3064 ..
 1 GRRFIGSLW RFLRAFG
 !:AA SEQUENCE 1.0
 ID -AD034378 standard; peptide; 14 AA.
 XX AC ADO34378;
 XX DT 12-AUG-2004 (first entry)
 XX DE Synthetic apolipoprotein-E mimicking peptide, SEQ ID NO 155.
 XX KW apolipoprotein-E mimicking polypeptide; antilipaeamic; cardiant;
 KW vasotropic; antiarteriosclerotic; cerebroprotective; antianginal;
 KW serum cholesterol; coronary artery disease; dysbetalipoproteinemia;
 KW atherosclerosis; myocardial infarction; stroke; embolus; angina;
 KW low-density lipoprotein; LDL; very low density lipoprotein; VLDL.
 XX OS Synthetic.
 XX PN W02004043403-A2.
 XX PD 27-MAY-2004.
 XX PF 13-NOV-2003; 2003WO-US036268.
 XX PR 13-NOV-2002; 2002US-0425821P.
 XX PA (UABR-) UAB RES FOUND.
 XX PI Anantharamiah GM, Garber DW, Datta G;
 XX WPI; 2004-411629/38.
 XX DT Synthetic apolipoprotein-E mimicking polypeptide useful for treating
 PT coronary artery disease, dysbetalipoproteinemia or atherosclerosis
 PT comprises an amino acid sequence.
 XX PS Claim 4; SEQ ID NO 155; 79pp; English.
 XX CC The invention relates to a novel synthetic apolipoprotein-E mimicking
 CC polypeptide. The invention further comprises an isolated nucleic acid
 CC encoding the synthetic apolipoprotein-E mimicking polypeptide; a vector,
 CC a host cell, a recombinant cell or a transgenic, non-human subject
 CC (including animal or plant) comprising the synthetic apolipoprotein-E
 CC mimicking polypeptide encoding polynucleotide; a composition comprising
 CC the synthetic apolipoprotein-E mimicking polypeptide and a carrier; and
 CC an monoclonal antibody that specifically binds to the synthetic
 CC apolipoprotein-E mimicking polypeptide. The synthetic apolipoprotein-E
 CC mimicking polypeptide has the following activities: antilipaeamic,
 CC cardiant, vasotropic, antiarteriosclerotic, cerebroprotective, and
 CC antianginal. The synthetic apolipoprotein-E mimicking polypeptide is
 CC useful for reducing serum cholesterol in a subject (including a mammal
 CC such as a mouse, rat, rabbit, cow, sheep, pig, human, monkey, ape,
 CC chimpanzee or orangutan); for treating coronary artery disease,
 CC dysbetalipoproteinemia or atherosclerosis; and for reducing the risk of
 CC myocardial infarction or stroke; for breaking an embolus in the subject;
 CC and also for treating angina. The synthetic apolipoprotein-E mimicking
 CC polypeptide enhances binding of low-density lipoprotein (LDL) or very low
 CC density lipoprotein (VLDL) to a cell and enhances degradation of LDL or
 CC VLDL by a cell. This sequence represents a synthetic apolipoprotein-E
 CC mimicking polypeptide of the invention.
 XX SQ Sequence 14 AA;
 AD034378 Length: 14 February 14, 2007 16:01 Type: P Check: 8241 ..
 1 GRRFYGSIW RFLR
 !:AA SEQUENCE 1.0
 ID -ADX96509 standard; protein; 671 AA.
 XX

AC ADX96509;
 XX DT 21-APR-2005 (first entry)
 XX DE Plant full length insert polypeptide seqid 59173.
 XX KW plant protectant; plant growth regulant; gene therapy; plant;
 KW recombinant DNA construct; physical array; plant breeding marker;
 KW cold tolerance; heat tolerance; drought tolerance; herbicide tolerance;
 KW extreme osmotic condition; pathogen tolerance; pest tolerance;
 KW growth rate; cell cycle pathway; disease resistance;
 KW galactomannan production; lignin production; plant growth regulator;
 KW yield; plant growth; plant development; seed oil; protein yield;
 KW protein content.
 XX OS Unidentified.
 XX PN US2004034888-A1.
 XX PD 19-FEB-2004.
 XX PF 28-APR-2003; 2003US-00425114.
 XX PR 06-MAY-1999; 99US-00304517.
 XX PR 05-NOV-2001; 2001US-00985678.
 XX PA (LIU/) LIU J.
 PA (ZHOU/) ZHOU Y.
 PA (KOVA/) KOVALIC D K.
 PA (SCRE/) SCREEN S E.
 PA (TABA/) TABASKA J E.
 PA (CAO/) CAO Y.
 XX PI Liu J, Zhou Y, Kovalic DK, Screen SE, Tabaska JE, Cao Y;
 XX WPI; 2004-180133/17.
 XX DT New recombinant DNA construct, useful for improving plant tolerance to
 PT cold, heat, drought, herbicides, extreme osmotic conditions, pathogens or
 PT pests, for conferring increased resistance to plant disease, or for
 PT improving yield.
 XX PS Claim 1; SEQ ID NO 59173; 15pp; English.
 XX CC The invention describes a recombinant DNA construct comprising a
 CC polynucleotide consisting of a sequence encoding an amino acid sequence
 CC available in electronic form from the US patent office at
 CC ftp.segdata.uspto.gov/sequence.html?DocID:2004034888. The polynucleotide
 CC of the invention are also useful in physical arrays of molecules and as
 CC plant breeding markers. The recombinant DNA construct is useful for
 CC improving plant tolerance to cold, heat, drought, herbicides, extreme
 CC osmotic conditions, pathogens or pests, for manipulating growth rate in
 CC plant cells by modification of the cell cycle pathway, for conferring
 CC increased resistance to plant disease, for producing galactomannan,
 CC lignin or plant growth regulators, for increasing the rate of homologous
 CC recombination in plants, for improving yield by modification of
 CC photosynthesis or carbohydrate, nitrogen or phosphorus use and/or uptake
 CC or by providing improved plant growth and development under at least one
 CC stress condition or for modifying seed oil or protein yield and/or
 CC content. This is the amino acid sequence of a plant full length insert
 CC polypeptide that can be used in the recombinant DNA construct of the
 CC invention.
 XX SQ Sequence 671 AA;
 ADX96509 Length: 671 February 14, 2007 16:01 Type: P Check: 8299 ..
 1 DPEPFPFR ARSGPARSPH APDPFGLATT GRPLPAPPRA MDVSVRYAHS
 51 PAHLAVLRD HAALRLVAA LPRLPFRAGEV ATEESTAGE AVADAVSAVV
 101 DRDRVPRRET PLHLAVLRD PVAADVLMSA GADWSLQAD GWSALQEAVC

```
151 TREEAII ARHYOPLAWA KWCRRLPRIL ASISRIRDFY MEITFHFEFF
201 VIPFSRIAP SDTYIRKRG AALRADMTLA GDFGRFQRS DQTFELGCDG
251 ARPEDAGKE LHPSGLIVLA HKDKEITDAL EGAGVOPTES EVAHEVALMS
301 KTNMYRPGID VTOAELVPHL NMRQERAEV VQGWAKVYD MLNLVLTVKS
351 RRVPGAMTDE ELFAMDGEEK NRGAEALDAE LDEVLTAEER KQLDSALRMG
401 NNEESEORC DEGTGAGHM DEHAAKDKK GWFNGGKKG AKGDDKPSKM
451 GSKDTSDFG KQKEKSGGK KGGSPAESL KHESEYKXGL RVLWLTPDF
501 PLKTDLEIPL LDVLANKVKA VRELLELTT KLPTGTFPVK IAIPIVTIR
551 VIVITKFEZ LQPLDEFATP PSSPTQFQDA KTKSESGSGS WYSWVGGRG
601 TQSSDSGDSR SWKDEVDPFH IPSDYTWVDA TEKKRRMKAK KAKSRRGPAR
651 KQSSKNATAG AHRPMDGFE E

!!AA SEQUENCE 1.0
ID ADY07006 standard; protein; 646 AA.
XX
AC ADY07006;
XX
DT 21-APR-2005 (first entry)
XX
DE Plant full length insert polypeptide seqid 62821.
XX
KW plant protectant; plant growth regulant; gene therapy; plant;
KW recombinant DNA construct; physical array; plant breeding marker;
KW cold tolerance; heat tolerance; drought tolerance; herbicide tolerance;
KW extreme osmotic condition; pathogen tolerance; pest tolerance;
KW growth rate; cell cycle pathway; disease resistance;
KW galactomannan production; lignin production; plant growth regulator;
KW yield; plant growth; plant development; seed oil; protein yield;
KW protein content.
XX
OS Unidentified.
XX
PN US2004034888-A1.
XX
PD 19-FEB-2004.
XX
PF 28-APR-2003; 2003US-00425114.
XX
PR 06-MAY-1999; 99US-00304517.
XX
PR 05-NOV-2001; 2001US-00985678.
XX
PA (LIU/) LIU J.
PA (ZHOU/) ZHOU Y.
PA (KOVA/) KOVALIC D K.
PA (SCRE/) SCREEN S E.
PA (TAB/) TABASKA J E.
PA (CAO/) CAO Y.
XX
PI Liu J, Zhou Y, Kovalic DK, Screen SE, Tabaska JE, Cao Y;
XX
DR WPI; 2004-180133/17.
XX
FT New recombinant DNA construct, useful for improving plant tolerance to
FT cold, heat, drought, herbicides, extreme osmotic conditions, pathogens or
FT pests, for conferring increased resistance to plant disease, or for
FT improving yield.
XX
PS Claim 1; SEQ ID NO 62821; 15pp; English.
XX
XX
CC The invention describes a recombinant DNA construct comprising a
CC polynucleotide consisting of a sequence encoding an amino acid sequence
CC available in electronic form from the US patent office at
CC ftp.seqdata.uspto.gov/sequence.html?DocID:2004034888. The polynucleotide
```

```
CC of the invention are also useful in physical arrays of molecules and as
CC plant breeding markers. The recombinant DNA construct is useful for
CC improving plant tolerance to cold, heat, drought, herbicides, extreme
CC osmotic conditions, pathogens or pests, for manipulating growth rate in
CC plant cells by modification of the cell cycle pathway, for conferring
CC increased resistance to plant disease, for producing galactomannan,
CC lignin or plant growth regulators, for increasing the rate of homologous
CC recombination in plants, for improving yield by modification of
CC photosynthesis or carbohydrate, nitrogen or phosphorus use and/or uptake
CC or by providing improved plant growth and development under at least one
CC stress condition or for modifying seed oil or protein yield and/or
CC content. This is the amino acid sequence of a plant full length insert
CC polypeptide that can be used in the recombinant DNA construct of the
CC invention.
XX
XX Sequence 646 AA;
XX
ADY07006 Length: 646 February 14, 2007 16:01 Type: P Check: 750
1 PSYDRPAGPA PPMAMDDVSK YAHSPAHLAV LRRDHAALRR LVAALPRLPR
51 AGEVATEEES VAGEAVADAV SAVIDRRDVP RRETPLHLAV RLDRPVAADI
101 LMSAGADWSL QNADGWSALQ EAVCTREEAI ATTIARHYQP LAWAKWCRL
151 PRILASISRI RDPYMEISPH FESSVIPFIG RIAPSDTYRI WKGAALRTD
201 MTLAGFDGFR IQRSDQTFLF LGDQARPEDA GKKELHSGSL IYLAHKDKEI
251 TDALEGAGVQ PTESEVAHEV ALMSKTNMYR PGIDVTQAEI VPHLNWRQEE
301 RTEAVGOWKA KYDMLNLVLV TVKSRVDPGA MTDEELFAMD GEEKNGRGAE
351 LDAELDEVLT ABERKOLDISA LRMGNNEEES EERGDEGDAG ADHTDASGVT
401 KDKKGWFGWG AKKGAKGDDK PSKVGSKDET SDPGKQKEG SGKKKKGSGS
451 AESVKHESEY KGLRPVLWL TPDPPLKTDE LIPLLDVLAN KYKAIIRLRE
501 LLTTKLPTGT FPVKIAPIV PTIRVIITFT KFELOQLDE FATPPSSPTQ
551 FQAKAKEPE GSGSWSVWK GGRGTQSGDS GDGRNWKDEV DPPHIPSDYT
601 WDATEKKR MRKAKAKSRR TTARKQSSKN TSSEGGHRPM MDGFEE
```